Mawson Infrastructure (MIGI) 10-K 1 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Wize Pharma, Inc.
Entity Central Index Key	0001218683
Trading Symbol	WIZP
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Document Fiscal Year Focus	2018
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Ex Transition Period	true
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Public Float			$ 945,458
Entity Common Stock, Shares Outstanding		9,917,550

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 3,183	$ 215
Restricted bank deposit		12
Marketable equity securities (Note 3)	32	323
Other current assets (Note 4)	180	40
Total current assets	3,395	590
PROPERTY AND EQUIPMENT, NET	8	5
TOTAL ASSETS	3,403	595
CURRENT LIABILITIES:
Trade payables	34	43
Other accounts payable (Note 7)	272	196
Current portion of license purchase obligation (Note 6)	250	250
Convertible loans, net (Note 8)	2,635	3,204
Total current liabilities	3,191	3,693
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT) (Note 12):
Preferred Stock A, with $0.001 par value per share - Authorized: 1,000,000 shares at December 31, 2018 and 2017; Issued and outstanding: 910 and 0 shares at December 31, 2018 and 2017, respectively	1
Common Stock, with $0.001 par value per share - 500,000,000 shares authorized at December 31, 2018 and 2017, respectively; 8,957,550 and 4,350,608 shares issued and outstanding at December 31, 2018 and 2017, respectively	9	4
Additional paid- in capital	30,272	23,397
Accumulated other comprehensive loss	(73)	(47)
Accumulated deficit	(29,997)	(26,452)
Total stockholders' equity (deficit)	212	(3,098)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 3,403	$ 595

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Consolidated Balance Sheets [Abstract]
Preferred stock A, par value	$ 0.001	$ 0.001
Preferred stock A, shares authorized	1,000,000	1,000,000
Preferred stock A, shares issued	910	0
Preferred stock A, shares outstanding	910	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	8,957,550	4,350,608
Common stock, shares outstanding	8,957,550	4,350,608

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development expenses	$ 694	$ 450
General and administrative expenses (Note 13a)	2,936	1,031
Operating loss	(3,630)	(1,481)
Financial income (expense), net (Note 13b)	351	(1,485)
Net loss	(3,279)	(2,966)
Addition to net loss (for EPS purpose)
Deemed dividend with respect to the repurchase of right for future investment	(292)	(3)
Net loss applicable to Common stockholders	(3,571)	(2,969)
Other comprehensive income (loss):
Foreign currency translation adjustments		(78)
Changes in unrealized gains on marketable equity securities		26
Other comprehensive income (loss)		(52)
Comprehensive loss	$ (3,279)	$ (3,018)
Basic and diluted net loss per share	$ (0.61)	$ (0.86)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	5,649,262	3,438,842

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Preferred Stock A		Common Stock		Additional paid-in capital	Treasury shares	Accumulated other comprehensive income (loss)	Accumulated deficit
Balance at Dec. 31, 2016	$ (831)			$ 3		$ 23,391	$ (747)	$ 5	$ (23,483)
Balance, Shares at Dec. 31, 2016				3,023,043
Beneficial conversion feature in respect to convertible loan	811					811
Classification of derivative liability for right to future investment into equity	280					280
Issuance of units consisting of common stock, preferred stock A and detachable warrants, net of issuance costs (Note 12h)	966			$ 1		965
Issuance of units consisting of common stock, preferred stock A and detachable warrants, net of issuance costs (Note 12h), shares				860,987
Conversion of Preferred stock into Common stock (Note 12i)
Exercise of options into common stock	21				[1]	21
Exercise of options into common stock, shares				31,439
Cancellation of treasury shares with respect to reverse recapitalization						(747)	747
Shares issued with respect to reverse recapitalization	298				[1]	298
Shares issued with respect to reverse recapitalization, Shares				435,139
Amount allocated to the repurchase of beneficial conversion feature in convertible loans	(2,800)					(2,800)
Amount allocated to the right for future investment - loan 2016 upon 2017 modification	44					44
Amount allocated to the right for future investment - loan 2017 upon 2017 modification	1,115					1,115
Deemed dividend with respect to the repurchase of right for future investment	(3)								(3)
Stock-based compensation	19					19
Foreign currency translation adjustment	(78)							(78)
Changes in unrealized gains on marketable equity securities	26							26
Net loss	(2,966)								(2,966)
Balance at Dec. 31, 2017	(3,098)			$ 4		23,397		(47)	(26,452)
Balance, Shares at Dec. 31, 2017				4,350,608
Cumulative effect adjustment from transition to ASU 2016-01 (see note 2b)								(26)	26
Issuance of shares with respect to exercise of PIPE warrants and right for future investment (see note 12d)	1,145			$ 1		1,144
Issuance of shares with respect to exercise of PIPE warrants and right for future investment (see note 12d), Shares				788,658
Issuance of units consisting of common stock, preferred stock A and detachable warrants, net of issuance costs (Note 12h)	3,915	$ 1		$ 3		3,911
Issuance of units consisting of common stock, preferred stock A and detachable warrants, net of issuance costs (Note 12h), shares		1,350		3,100,000
Conversion of Preferred stock into Common stock (Note 12i)			[1]		[1]
Conversion of Preferred stock into Common stock (Note 12i), Shares		(440)		440,000
Amount allocated to the repurchase of beneficial conversion feature in convertible loans	(1,918)					(1,918)
mount allocated to the right for future investment - loan 2016 upon 2018 modification (note 8)	952					952
Amount allocated to the right for future investment - loan 2017 upon 2018 modification (note 8	1,444					1,444
Deemed dividend with respect to the repurchase of right for future investment	(292)								(292)
Stock-based compensation	1,343			$ 1	[1]	1,342
Stock-based compensation, Shares				278,284
Net loss	(3,279)								(3,279)
Balance at Dec. 31, 2018	$ 212	$ 1		$ 9		$ 30,272		$ (73)	$ (29,997)
Balance, Shares at Dec. 31, 2018		910		8,957,550
[1]	Representing amount less than $1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (3,279)	$ (2,966)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2	1
Stock-based compensation	1,289	19
Unrealized loss on marketable equity securities	33
Amortization of discounts and issuance costs related to convertible loans		1,122
Amortization of premium related to convertible loans (Notes 8 and 13)	(2,149)
Accrued interest on convertible loans (Notes 8 and 13)	56	47
Loss from extinguishment of convertible loans (Notes 8 and 13)	1,709	61
Change in the fair value of derivative liability for right to future investment (Notes 8 and 13)		246
Change in the fair value of license purchase obligation (Note 6)		3
Change in:
Other current assets	(86)	(33)
Trade payables	(9)	30
Other accounts payable	76	(40)
License purchase obligation	150	146
Net cash used in operating activities	(2,208)	(1,364)
Cash flows from investing activities
Purchase of property and equipment	(5)	(4)
Proceeds from sale of marketable equity securities	258
Net cash provided by (used in) investing activities	253	(4)
Cash flows from financing activities
Proceeds from loans from controlling stockholder		82
Proceeds from issuance of convertible loans, net of issuance costs (Note 8)		625
Proceeds from issuance of shares with respect to exercise of PIPE warrants and right for future investment	1,145
Proceeds from issuance of units consisting of common stock, preferred stock A and warrants (Note 12c)	3,915	966
Proceeds from exercise of options into common stock		21
Repayment of license purchase obligation	(150)	(156)
Net cash provided by financing activities	4,910	1,538
Effect of exchange rate change on cash, cash equivalents and restricted cash	1	17
Change in cash, cash equivalents and restricted cash	2,956	187
Cash, cash equivalents and restricted cash at the beginning of the year	227	40
Cash, cash equivalents and restricted cash at the end of the year	3,183	227
Supplemental disclosure of non-cash financing activities:
Classification of derivative liability for right to future investment into equity		280
Acquisition of marketable equity securities as part of the recapitalization		298
Increase in other current assets through equity	54
Deemed dividend with respect to the repurchase of right for future investment	292	3
Conversion of Preferred stock into Common stock
Amount allocated to the repurchase of beneficial conversion feature in convertible loans	(1,918)	(2,800)
Amount allocated to the right for future investment - loan 2016 upon 2018 modification	952
Amount allocated to the right for future investment - loan 2017 upon 2018 modification	$ 1,444

General

General	12 Months Ended
	Dec. 31, 2018
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. Wize Pharma, Inc. (the “Company” or “Wize”) was incorporated in the State of Delaware. On November 16, 2017, the Company completed the acquisition of Wize Pharma Ltd., an Israeli company (“Wize Israel”) by way of a reverse triangular merger. Wize Israel is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (“DES”). Commencing August 30, 2016, Wize Israel manages most of its activity through OcuWize Ltd., a wholly-owned Israeli subsidiary which manages and develops most of the Company’s activity under the License Agreement (see also Note 5). In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the “License Agreement”) with Resdevco Ltd. (“Resdevco”), whereby Resdevco granted to Wize Israel an exclusive license to purchase, market, sell and distribute a formula known as LO2A (“LO2A”) in the United States, Israel, Ukraine and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (“CCH”) and Sjögren’s syndrome (“Sjögren’s”). Pursuant to the LO2A License Agreement, Wize Israel is required to pay Resdevco certain royalties for sales in the licensed territories based on an agreed-upon price per unit of either $0.60, in the United States, Israel and Ukraine, or in the low single digits of US Dollars, in the People’s Republic of China, payable on a semi-annual basis, subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In July 2018, the Company paid Resdevco royalties in the amount of $185. Following the Merger (as defined below) transaction as described in Note 1d, the business of Wize Israel became the ongoing business of the Company and the Company is defined as a “smaller reporting company”, according to Item 10(f)(1) of Regulation S-K, as promulgated by the United States Securities and Exchange Commission (the “SEC”). For discussion of a financing transaction in October 2018, see also Note 12j. b. Going concern uncertainty and management plans: The Company has not yet generated any material revenues from its current operations, and therefore is dependent upon external sources for financing its operations. As of December 31, 2018, the Company has an accumulated deficit of $29,997. In addition, in the years ended December 31, 2018, and December 31, 2017, the Company reported losses and negative cash flows from operating activities. Furthermore, unless the Company can extend the maturity date, or obtain additional financing, the convertible loans in the aggregate principal amount of $1,353 will become due in May 2019 (refer to note 15). Management considered the significance of such conditions in relation to the Company’s ability to meet its current and future obligations and determined that such conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. Until such time as the Company generates sufficient revenue to fund its operations (if ever), the Company plans to finance its operations and repay existing indebtedness through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short-term and long-term loans. There can be no assurance that the Company will succeed in obtaining the necessary financing to continue its operations as a going concern. c. Risk factors: As of December 31, 2018, the Company had an accumulated deficit of $29,997. The Company has historically incurred net losses and is not able to determine whether or when it will become profitable, if ever. To date, the Company has not commercialized any products or generated any material revenues from product sales and accordingly it does not have a revenue stream to support its cost structure. The Company’s losses have resulted principally from costs incurred in development and discovery activities and general and administrative expenses. The Company expects to continue to incur losses for the foreseeable future, and these losses will likely increase as it: ■ ■ ■ ■ ■ ■ ■ No certainty exists that the Company will be able to complete the development of LO2A for CCH, Sjögren’s or any other ophthalmic disorder, due to financial, technological or other difficulties. If LO2A fails in clinical trials or does not gain regulatory clearance or approval, or if LO2A does not achieve market acceptance, the Company may never become profitable. Even if the Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The Company’s inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows. Moreover, the Company’s prospects must be considered in light of the risks and uncertainties encountered by an early-stage company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval and market acceptance of its products are uncertain. There can be no assurance that the Company’s efforts will ultimately be successful or result in revenues or profits. d. Merger transaction: On May 21, 2017, the Company and a wholly-owned private Israeli subsidiary of the Company, Bufiduck Ltd. (“Merger Sub”), and Wize Israel, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things, Merger Sub merged with and into Wize Israel, with Wize Israel becoming a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). On November 16, 2017, the Merger was closed (the “Closing Date”). Upon the Closing Date of the Merger, each issued and outstanding ordinary share of Wize Israel was automatically converted into 4.1445791236989 shares (the “Exchange Ratio”) (such number not being converted as per the Reverse Stock Split described in Note 12c) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). As a result, an aggregate of 3,915,469 shares, or approximately 90% of the issued and outstanding Common Stock were issued to Wize Israel’s shareholders. The pre-Merger stockholders of the Company retained an aggregate of 435,053 shares, or approximately 10% of the issued and outstanding Common Stock. Wize Israel’s ordinary shares were delisted from the Tel Aviv Stock Exchange (“TASE”) and there is no longer a public trading market for Wize Israel’s ordinary shares in Israel. The Merger between the Company and Wize Israel became effective on November 16, 2017, and following such Merger, Wize Israel activities are the sole activities of the Company. The Common Stock is currently quoted in the United States on the over-the-counter (“OTCQB”) under the symbol “WIZP.” The Merger was accounted for as a reverse recapitalization which is outside the scope of ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, was considered a non-operating public shell, and was therefore not a business as defined in ASC 805. Under reverse capitalization accounting, Wize Israel was considered the acquirer for accounting and financial reporting purposes. The Merger was accounted for in a manner that is substantially the same as a reverse acquisition under ASC 805, except that any excess fair value of the consideration transferred over the net fair value of the monetary assets of the Company was recognized as a reduction of equity. The annual consolidated financial statements of Wize Israel reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. The annual consolidated financial statements include the accounts of the Company since the Closing Date of the reverse capitalization and the accounts of Wize Israel since its inception.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). a. Use of estimate in preparation of financial statements: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and freestanding financial instruments related to convertible loans and rights to future investment and the determination whether modification of terms of financial instruments is substantial. b. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated upon consolidation. c. Functional currency: Prior to the Merger, as Wize Israel activities were conducted in Israel and most of its financing was denominated and determined in New Israel Shekels (NIS), management has determined that the functional currency of Wize Israel was NIS. Following to the Closing Date of the Merger, the Company aims to direct its main operations in the United States market. In addition, following to the Closing Date of the Merger, the current convertible loans which were previously denominated in NIS, were changed into U.S. dollars terms, including their principal and conversion price. Similarly, the Company issued warrants eligible for exercise for the Company’s shares of common stock at an exercise price denominated in U.S. dollars. Also, the management believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, as of that date, the functional currency of the Company was changed into the U.S. dollar. The reporting currency of the consolidated financial statements is U.S. dollars. Pre-merger, Wize Israel and OcuWize results were translated into U.S. dollars in accordance with the standards of the Financial Accounting Standards Board (“FASB”). Accordingly, assets and liabilities were translated from NIS to U.S. dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is different than the U.S. dollar) were reported in other comprehensive income and are reflected in equity, under “accumulated other comprehensive income (loss)”. As a result of adoption of ASU 2016-01, as discussed in note 2v, accumulated other comprehensive income as of December 31, 2018 consists solely of foreign currency translation adjustment. Balances denominated in, or linked to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. The following table presents data regarding the dollar exchange rate of relevant currencies: As of December 31, % of change 2018 2017 2018 2017 USD 1 = NIS 3.748 3.467 8.1 (9.8 ) d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. For presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total amounts. December 31 2017 Cash and cash equivalents $ 215 Restricted cash 12 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 227 There were no restricted cash amounts as of December 31, 2018. e. Restricted bank deposit: Restricted bank deposit is a deposit with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including accrued interest and represents cash which is used as collateral for Wize Israel’s credit card. f. Marketable equity securities: Until December 31, 2017, the Company’s investment in marketable equity securities was classified as available-for-sale carried at fair value based on the quoted market price, with unrealized gains and losses reported as a separate component of stockholders’ deficit under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. The Company accounted for these marketable equity securities as available-for-sale carried at fair value since these marketable equity securities were considered available to be converted into cash to fund Company’s current operations. The Company was required to recognize an impairment charge when a decline in the fair value of its investments in securities was below the cost basis of such securities and was determined to be other than temporary. Factors considered in making such a determination included the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company’s intent to sell. For securities that were deemed other-than-temporarily impaired, an impairment was recognized as the difference between the cost basis of the impaired equity security and the fair value on the measurement date, as part of financial income, net in the statement of comprehensive loss. The fair value on measurement date was considered the equity security’s new cost basis. As of December 2017, the Company has not recorded loss from impairment. Commencing January 1, 2018, following the effective date of ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” (ASU 2016-01), the Company’s investment in marketable equity securities which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value with any changes in fair value recognized periodically in net income. g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and electronic equipment 33 Furniture and office equipment 10 h. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360 “Property, plant and equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During the years ended December 31, 2018 and 2017, no impairment losses have been identified. i. Research and development expenses: Research and development expenses are charged to the statement of comprehensive loss as incurred. In-Process Research and Development assets (“IPR&D”), acquired in an asset acquisition (i.e. assets acquired outside a business combination transactions) that are to be used in a research and development project which are determined not to have an alternative future use are charged to expense at the acquisition date in accordance with ASC 730, “Research and Development”. j. Severance pay: Wize Israel has two employee as of December 31, 2018 and 2017. Wize Israel’s liability for severance pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), pursuant to which all Wize Israel’s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee’s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2018 and 2017. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. Severance expenses for the years ended December 31, 2018 and 2017 amounted to $10 for both periods. k. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2018 and 2017, no liability for unrecognized tax positions has been recognized. l. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted bank deposits. Cash and cash equivalents and restricted bank deposits are invested in major banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. m. Convertible loans: Allocation of proceeds: The proceeds received upon the original issuance of the 2016 Loan together with a freestanding derivative financial instrument (derivative liability for right to future investment) were allocated to the financial instruments issued based on the residual value method. The detachable derivative financial instrument related to the 2016 loan was recognized based on its fair value and the remaining amount of the proceeds was allocated to the 2016 Loan component. Beneficial Conversion Features (“BCF”): a. Upon initial recognition, the Company has considered the provisions of ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity”, and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, “Debt - Debt with Conversion and Other Options” which clarifies the accounting for instruments with BCF or contingently adjustable conversion ratios, and has applied the BCF guidance to determine whether the conversion feature is beneficial to the investor. The BCF was calculated by allocating the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative liability for future investment (see also Note 8)) included in the transaction, and by measuring the intrinsic value of the conversion option based on the effective conversion price as a result of the allocated proceeds. The intrinsic value of the conversion option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method. b. Upon initial recognition, the Company has considered the provisions of ASC 815-15, “Derivatives and Hedging - Embedded Derivatives” (“ASC 815-15”), and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, since its terms do not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash. Furthermore the Company applied ASC 470-20 which clarifies the accounting for instruments with BCF or contingently adjustable conversion ratios. Pursuant to ASC 470-20-30, the amount of the BCF with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion price (i.e. the entire proceeds received for the 2017 Loan) and the aggregate fair value of the common stock and other securities (which consist of the Investment Option) into which the 2017 Loan is convertible. As such difference was determined to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned to the BCF was limited to the amount of the entire proceeds. c. Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, “Debt – Debt with conversion and other options” to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following the extinguishment of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors. d. Modifications or exchanges Modifications to, or exchanges of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions of ASC 470-50, “Debt- Modification and Extinguishments”. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. Under ASC 470-50, modifications or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new debt and original instrument are substantially different. The instruments are considered “substantially different” when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the debt instruments are not considered to be substantially different, except in the following two circumstances (i) The transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the modification or exchange or (ii) The transaction adds a substantive conversion option or eliminates a conversion option that was substantive at the date of the modification or exchange. If the original and new debt instruments are considered as “substantially different”, the original debt is derecognized and the new debt is initially recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable. If a convertible debt instrument with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument. The gain or loss on the extinguishment of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the allocated reacquisition price. Modifications to, or exchanges of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments before and after the modification or exchange are substantially different. If the original and new equity instruments are considered as “substantially different”, the excess fair value of the allocated reacquisition price over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as a deemed dividend. Issuance costs of convertible loan: a. Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) are presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCF if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred. b. Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan also discussed in Note 8 (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan. n. Fair value of financial instruments: ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the investments are categorized as Level 3. The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their fair value due to the short-term maturities of such instruments. Fair value of the marketable equity securities is determined based on a Level 1 input. Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Company would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency or stock prices, as applicable. The fair value measurement of the derivative liability for right to future investment (which were classified to equity during 2017) and the financial instruments included under 2017 Loan and 2016 Loan (see note 8) are classified within Level 3. Following each of the modifications described in Note 8, Wize Israel’s management engaged an external appraiser that measured the fair value of the financial instruments exchanged or modified, as further described in Note 8 and in the following paragraph. The following tabular presentation reflects the components of the derivative liability associated with rights to future investment during the year ended December 31, 2017: Fair value Balance at December 31, 2016 $ 34 Change in the fair value of derivative liability 246 Reclassification of derivative liability into equity (*) (280 ) Balance at December 31, 2017 $ - (*) Upon the December 2017 modification, and in accordance with ASC 815-40 “Derivatives and Hedging, Contracts in Entity’s Own Equity”, it was determined that the right to future investment is eligible to be considered as indexed to the Company’s own stock. Accordingly, the fair value of the Right of Future Investment immediately prior to the Modification Date (December 2017) which amounted to NIS 1,042,000 (approximately $280 according to the exchange rate as of the Modification Date) was reclassified from a derivative liability to additional paid-in capital. o. Legal and other contingencies: The Company accounts for its contingent liabilities in accordance with ASC 450 “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2018, the Company is not a party to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred. p. Treasury shares: Shares held by the Company are presented as a reduction of equity, at their cost to the Company as treasury stock, until such shares are retired and removed from the account. q. Derivatives: The Company applies the provisions of ASC Topic 815, “Derivatives and Hedging” pursuant to which all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. As of December 31, 2016, the balance of derivative instruments consisted of derivative liability for right to future investment in an amount of $34 (see also n. above and r. below), and is stated at fair value. As of December 31, 2018 and 2017, there were no financial instruments required to be accounted as derivatives (see also n. above and r. below). During the years ended December 31, 2018 and 2017, the Company did not designate any financial instruments for hedging purposes. r. Derivative liability for right to future investment: Upon initial recognition, the Company reviewed the terms of such obligation and determined that it is not eligible to be classified as a component of permanent equity, as such instrument permitted the holder to receive a variable number of shares of common stock upon exercise, by investment of cash amount that will be determined at the discretion of the holder (up to a pre-determined cap). Accordingly, such financial instrument was accounted for as a derivative liability and as such was measured upon initial recognition and re-measured at subsequent reporting periods at fair value. Changes in the fair value were recorded in the consolidated statement of comprehensive loss within the caption “financial expense, net”. Upon the December 2017 modification, and in accordance with ASC 815-40 “Derivatives and Hedging, Contracts in Entity’s Own Equity”, it was determined that the right to future investment, eligible to be considered as indexed to the Company’s own stock and as a result the derivative liability for right to future investment was reclassified into additional paid-in capital (see also Note 8). s. Series A Warrants with Down-Round Protection Commencing January 1, 2018 and following the early adoption of Accounting Standard Update (ASU) No. 2017-11, “I. Accounting for certain financial instruments with Down Round Features” (ASU 2017-11) as described in Note 2.t, the Company disregard certain down-round features when assessing whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification. Based on its evaluation, management has determined that Series A Warrants (the “Warrants”) that were issued on October 2018, as part of a private placement, as described in Note 12J, which include a down-round protection that would adjust the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, are eligible for equity classification. In accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when the exercise price of the Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation. During the period from issuance of the Warrants and throughout December 31, 2018, there were no events that require a downward adjustment of the current exercise price of the Warrants. t. Basic and diluted loss per share: Basic loss per share is computed by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of common stock outstanding during the period. Securities that may participate in dividends with the common stock (such as the convertible Series A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of net loss, such participating securities are included in the computation, since the holders of such securities have a contractual obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares). In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and rights for future investment issued or granted using the “treasury stock method” and upon the conversion of 2017 Loan and 2016 Loan using the “if-converted method”, if the effect of each of such financial instruments is dilutive. For the years ended December 31, 2018 and 2017, all outstanding stock options and other convertible instruments have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2018 and 2017, is as follows: Year ended 2018 2017 Numerator: Net loss $ (3,279 ) $ (2,966 ) Add: Loss attributed to preferred stock (*) 147 - Less: Deemed dividend with respect to right for future investment $ (292 ) $ (3 ) Net loss applicable to stockholders of Common Stock $ (3,424 ) $ (2,969 ) Denominator: Shares of common stock used in computing basic and diluted net loss per share 5,649,262 3,438,842 Net loss per share of Common stock, basic and diluted $ (0.61 ) $ (0.86 ) (*) During the year ended December 31, 2018 the Company issued preferred stock as part of the October 2018 transaction. These preferred shares are participating securities as described in Note 12.j. During the years ended December 31, 2018 and 2017 there were no other potentially dilutive instruments. u. Accumulated other comprehensive loss: Accumulated other comprehensive loss, presented in stockholders’ deficit, includes (i) gains and losses that were incurred from the translation of the pre-merger results of Wize Israel and OcuWize to the reporting currency (see also Note 2c) and (ii) unrealized gain from the change in the fair value of marketable equity securities that were classified as available-for-sale until December 31, 2017. The components of accumulated other comprehensive income (loss) as of December 31, 2017 and 2018 were as follows: Total accumulated other comprehensive income (loss) Balance at January 1, 2017 $ (47 ) Cumulative effect adjustment as a result from transition to ASU 2016-01 (26 ) Balance at December 31, 2018 $ (73 ) v. Stock-based compensation: Stock-based compensation to employees is accounted for in accordance with ASC 718, “Compensation

Marketable Equity Securities

Marketable Equity Securities	12 Months Ended
	Dec. 31, 2018
Marketable Equity Securities [Abstract]
MARKETABLE EQUITY SECURITIES	NOTE 3:- MARKETABLE EQUITY SECURITIES The Company owns 52,249 ordinary shares of Can-Fite representing approximately 0.12% of Can-Fite’s issued and outstanding share capital as of December 31, 2018. This is an asset held by the Company as of the Closing Date of the Merger and was initially recorded at fair value (quoted market) on the Closing Date. Commencing January 1, 2018, such shares with readily determinable fair value are classified at fair value with changes carried to income or loss.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2018
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	NOTE 4:- OTHER CURRENT ASSETS December 31, 2018 2017 Prepaid expenses $ 97 $ 3 Receivables from governmental authorities 75 37 Other 8 - $ 180 $ 40

License Agreement

License Agreement	12 Months Ended
	Dec. 31, 2018
License Agreement [Abstract]
LICENSE AGREEMENT	NOTE 5:- LICENSE AGREEMENT In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the “License Agreement”) with Resdevco Ltd. (“Resdevco”), whereby Resdevco granted to Wize Israel an exclusive license to purchase, market, sell and distribute a formula known as LO2A (“LO2A”) in the United States, Israel, Ukraine and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (“CCH”) and Sjögren’s syndrome (“Sjögren’s”). Pursuant to the LO2A License Agreement, Wize Israel is required to pay Resdevco certain royalties for sales in the licensed territories based on an agreed-upon price per unit of either $0.60, in the United States, Israel and Ukraine, or in the low single digits of US Dollars, in the People’s Republic of China, payable on a semi-annual basis, subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In July 2018, the Company paid Resdevco royalties in the amount of $185. The fair value of the Minimum Commitment to pay royalties as stated as of its initial recognition date was calculated based on an estimate of the fair value of the payments set in the License Agreement in accordance with the dates set in the License Agreement using a discount rate of 21%, which reflected, among other things, Wize Israel’s estimate of its equity rate as of that date. At initial recognition, the fair value of the Minimum Commitment was estimated in an amount of $397. As of December 31, 2018, the current liability to pay future royalties amounts to $250 (see also Note 6). On February 28, 2019, the Company terminated the distribution agreements in the territory of Ukraine.

License Purchase Obligation

License Purchase Obligation	12 Months Ended
	Dec. 31, 2018
License Purchase Obligation [Abstract]
LICENSE PURCHASE OBLIGATION	NOTE 6:- LICENSE PURCHASE OBLIGATION a. As noted in Note 5, as consideration for the License Agreement, Wize Israel undertook to pay a Minimum Commitment of licensing fees and royalties of no less than $500 in the first three years of the agreement. An amount of $100 was paid in May 2015, upon signing the License Agreement and amounts of $150 and $150 were paid in January 2016 and July 2017, respectively. In July 2017, Wize Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 will be reduced to $150 for 2018 and 2019. If Wize Israel obtains an FDA marketing license during 2019, the Company will be required to pay Resdevco the remainder of the payment of 2019. Consequently, during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the 2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 the Company has recognized an amount of $150 as a liability in respect to the 2019 minimum commitment. Such amount is reflected as an expense under research and development expenses in 2017 and 2018 as applicable. In February 2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through 2021, and then annual payments of $475,00 0 per year, and shall pay Resdevco $650,000 within two years after receipt of FDA approval for eye drops utilizing the licensed technology. On December 26, 2017, Wize Israel entered into an amendment to the License Agreement with Resdevco (the “Third Amendment”) which includes (i) China in the list of Licensed Territories, (ii) the size and timing of royalty payments, including the minimum annual royalty payments, payable by Wize Israel to Resdevco in connection with its distribution activities in China, and (iii) an undertaking by Wize Israel to include in the distribution agreement to be entered into with the Chinese Distributor that the Chinese Distributor will transfer the Chinese market license to Resdevco upon termination of the distribution agreement. On May 31, 2018, The Company entered into a distribution agreement with the Chinese distributor. As a result of entering into the agreement above, the term of the Third Amendment did not expire on June 1, 2018. b. The following table details the repayment dates of the remaining Minimal Commitment on the financial liability and the balance in the consolidated financial statements: As of December 31, 2018 2017 Repayment dates: January 1, 2018 $ - $ 250 January 1, 2019 250 - Remaining balance 250 250 Current liability 250 250 Non-current liability - - Total $ 250 $ 250 c. On January 21, 2018, Resdevco agreed to postpone the minimum royalty payment obligation amounting to $150 from January 1, 2018 to July 29, 2018 (see also note 5).

Other Accounts Payable

Other Accounts Payable	12 Months Ended
	Dec. 31, 2018
Other Accounts Payable [Abstract]
OTHER ACCOUNTS PAYABLE	NOTE 7:- OTHER ACCOUNTS PAYABLE December 31, 2018 2017 Employees and payroll accruals (*) $ 130 $ 101 Accrued expenses 142 95 $ 272 $ 196 (*) As of December 31, 2018 and 2017, most of the sum refers to a debt to the Company’s Chief Executive Officer, with whom the Company had reached an agreement regarding postponing the payment date. The debt is expected to be paid in the foreseeable future.

Convertible Loans

Convertible Loans	12 Months Ended
	Dec. 31, 2018
Convertible Loans [Abstract]
CONVERTIBLE LOANS	NOTE 8:- CONVERTIBLE LOANS a. On March 20, 2016, Wize Israel entered into an agreement (as amended on March 30, 2016, the “2016 Loan Agreement”) pursuant to which Rimon Gold Assets Ltd. (“Rimon Gold”) extended a loan in the principal amount of up to NIS 2 million (approximately $531 according to an exchange rate at 2016 loan originate date), which bears interest at an annual rate of 4% (the “2016 Loan”). Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), the 2016 Loan had a maturity date of December 31, 2018. Regarding the modification of the maturity date of the 2016 loan in October 2018, see also Note 8b. Under the 2016 Loan Agreement, Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000 (approximately $26 according to an exchange rate at 2016 loan origination date), into Wize Israel ordinary shares at a conversion price per share of NIS 15.2592 (approximately $3.84), subject to adjustments for stock splits and similar events set forth in the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96). As a result of the 2017 Loan Amendment (as defined below), the aggregate principal amount of the 2016 Loan is $531 and the conversion price per share for the 2016 Loan was adjusted to $0.9768. In addition, under the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), Rimon Gold had the right (the “2016 Investment Right”), until June 30, 2019, to invest up to $797, in the aggregate, at an agreed price per share, which was adjusted based on the Exchange Ratio from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment (as defined below), from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events). Regarding modification to extend the term of the 2016 investment right in October 2018, see also Note 8b. Rimon Gold was entitled, under certain circumstances, to demand repayment of the 2016 Loan, including among others: (i) if Wize Israel breaches or fails to perform or is shown to have made a false statement, under the 2016 Loan Agreement or the Security Agreements; (ii) any failure of Wize Israel to make a timely payment; (iii) upon the appointment of a receiver; (iv) the imposition of a lien on a material asset of Wize Israel (v) if Wize Israel files a motion to stay proceedings; (vi) upon the expiration or termination of the License Agreement or if any party is in material breach of the License Agreement or if any party notifies the other of its intention to terminate the License Agreement; (vii) an adverse material change; or (viii) upon the non-performance of Wize Israel pursuant to the 2017 Loan Agreement, see also Note 8b. The 2016 Loan Agreement and the Security Agreements contain a number of restrictive covenants that limit Wize Israel's operating flexibility. These covenants include, among other things, limitations on the creation of liens; on the incurrence of indebtedness; on dispositions of assets, mergers, acquisitions and other change of control transactions; on changes in the general nature of the Company's business; restrictions on payments to related parties; restrictions on conducting rights offerings, and on the distribution of dividends. The Company believes it is in compliance with the 2016 loan covenants through the date of the financial statements. On January 15, 2017, Wize Israel entered into the loan agreement (the “2017 Loan Agreement”) with Ridge Valley Corporation (“Ridge”), and, by way of entering into assignments and assumption agreements following such date, also with Rimon Gold and Shimshon Fisher (“Fisher,” and together with Ridge and Rimon Gold, the “2017 Lenders”), whereby each of the lenders extended a loan in the principal amount of up to NIS 1 million (approximately $274 according to an exchange rate at 2017 loan originate date) and in the aggregate principal amount of up to NIS 3 million (approximately $822 according to an exchange rate at 2017 loan originate date), which bears interest at an annual rate of 4% (the “2017 Loan”, and together with the 2016 Loan, the “Loans”). Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment (as defined below), the 2017 Loan had a maturity date of December 31, 2018. Regarding the modification of the maturity date of the 2017 loan in October 2018, see also Note 8b. Under the 2017 Loan Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017 Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date), that the lender provided to Wize Israel (each such portion converted into Wize Israel ordinary shares at a conversion price per share equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the “2017 Loan Conversion Price”). As a result of the 2017 PIPE (see also Note 12b), the 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment (as defined below), the aggregate principal amount of the 2017 Loan is $822 and the 2017 Loan Conversion Price was adjusted to $1.1112. See “2017 Loan Amendment” below. In addition, under the 2017 Loan Agreement, as modified by the 2017 Loan Amendment (as defined below), the 2017 Lenders had the right (the “2017 Investment Right”), until June 30, 2019, to invest up to $1,233, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted in December 2017, based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock splits or similar events). Regarding modification to extend the term of the 2017 investment right in October 2018, see also Note 8b. Ridge was entitled, under certain circumstances, to demand repayment of the 2017 Loan, including: (i) if Wize Israel breaches or fails to perform or is shown to have made a false statement, under the 2017 Agreement or the Security Agreements; (ii) any failure of Wize Israel to make a timely payment; (iii) upon the appointment of a receiver; (iv) the imposition of a lien on a material asset of Wize Israel; (v) if Wize Israel files a motion to freeze proceedings; or (vi) an adverse material change. The 2017 Loan contains a number of restrictive covenants that limit the Wize Israel's operating flexibility. These covenants include, among other things, limitations on the creation of liens; on the incurrence of indebtedness; on dispositions of assets, mergers, acquisitions and other change of control transactions; on changes in the general nature of Wize Israel's business; restrictions on payments to related parties; and on the distribution of dividends. The Company believes it is in compliance with the 2017 loan covenants through the date of the financial statements. The Company has considered the provisions of ASC 815-15, “Derivatives and Hedging – Embedded Derivatives” (“ASC 815-15”), and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, does not meet the definition of a derivative in accordance with the provisions of ASC 815-10, since its terms do not require or permit net settlement. Thus, the conversion feature does not meet the characteristic of being readily convertible to cash. Wize Israel applied ASC 470-20, “Debt - Debt with Conversion and Other Options” which clarifies the accounting for instruments with BCF or contingently adjustable conversion ratios. Pursuant to ASC 470-20-30, the amount of the BCF with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion price (i.e. the entire proceeds received for the 2017 Loan) and the aggregate fair value of the common stock and other securities (which consist of the Investment Option) into which the 2017 Loan is convertible. As such difference was determined to be greater than the amount of the entire proceeds received for the 2017 Loan, the amount of the discount assigned to the BCF was limited to the amount of the entire proceeds. Accordingly, the BCF amounting to NIS 3,000,000 (approximately $811 according to the average exchange rate at the commitment date) was recorded as a discount on the 2017 Loan with a corresponding amount credited directly to equity as additional paid-in capital. As a result, upon initial recognition, the amount related to the 2017 Loan was NIS 0. After the initial recognition, the discount on the 2017 Loan is amortized as interest expense over the term of the 2017 Loan. 2017 loan amendment On December 21, 2017, the Company entered into an amendment (the “2017 Loan Amendment”) to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS: 2017 Loan 2016 Loan Aggregate principal amount $ (*) 822 $ 531 Conversion price per Company’s share $ 1.1112 $ 0.9768 Aggregate maximum of Right to Future Investment $ (**) 1,233 $ 797 Exercise Price of Right to Future Investment $ 1.332 $ 1.308 (*) Principal loan amount of $274 for each of the three 2017 Lenders. (**) Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders. Accordingly, each of the modified financial instruments were initially recorded at fair value. Then, the total fair value of the modified financial instruments related to the 2017 Loan and 2016 Loan (the “Reacquisition Price”) was allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $2,104 was allocated to the 2016 Loan and an aggregate amount of $2,985 was allocated to the 2017 Loan. The difference between the Reacquisition Price that was allocated to the Right to Future Investment amounting to $704 which was included in the 2016 Loan and its fair value as of that date amounting to $701 was recorded directly to additional paid in capital (as a deemed dividend in an amount of $3). In addition, the Reacquisition Price that was allocated to the newly detachable right to future investment related to the 2017 Loan was recognized directly to additional paid-in capital. Such financial instruments amounted to $1,115 as of December 21, 2017. The remaining amount of the Reacquisition Price that was allocated to the 2017 Loan and 2016 Loan which included an embedded BCF was firstly attributed to the repurchase of the BCF based on the intrinsic value of the conversion feature at the extinguishment date and the residual amounts, were allocated to the 2017 Loan and 2016 Loan. The difference between such residual amounts and the carrying value of the 2017 Loan and 2016 Loan was recorded as loss on extinguishment amounting to $61 of the 2017 Loan and 2016 Loan. b. 2018 loan amendment In connection with the Purchase Agreement, on October 19, 2018 (“2018 modification date”) the Company and its wholly-owned subsidiary Wize Pharma Ltd. (“Wize Israel”) entered into an amendment to the existing convertible loan (the “Amendment”). Pursuant to Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement (see note 12j.), and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date. According to ASC 470-50, each of the modified financial instruments were measured at fair value. Then, the total fair value of the modified financial instruments related to the 2017 Loan and 2016 Loan (the “Reacquisition Price”) was allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $2,314 was allocated to the 2016 Loan and an aggregate amount of $3,286 was allocated to the 2017 Loan and the related 2016 and 2017 right to future investment. The difference between the Reacquisition Price that was allocated to the Right to Future Investment amounting to $874 which was included in the 2016 Loan and its fair value as of that date amounting to $764 was recorded directly to additional paid in capital (as a deemed dividend in an amount of $110). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $1,336 which was included in the 2017 Loan and its fair value as of that date amounting to $1,154, was recorded directly to additional paid-in capital (as a deemed dividend in an amount of $182). The difference between reacquisition price that was allocated to the 2017 loan and to the 2016 loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as gain on extinguishment amounting to $1,709 of the 2017 Loan and 2016 Loan. The below table describes the roll forward of 2017 Loan and 2016 Loan for the year ended December 31, 2018 and 2017: December 31, 2018 2017 Opening balance $ 3,204 $ 289 Proceeds from issuance of 2017 loan, net of issuance cost — 811 Recognition of BCF as a discount of 2017 Loan — (811 ) Amortization of premium related to convertible loans prior to 2018 modification (1,458 ) — Amortization of discounts resulting from BCF and derivative liability and debt issuance costs related to 2017 Loan and 2016 Loan — 1,122 Accrued interest on 2017 Loan and 2016 Loan 56 47 Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments (1,680 ) (1,458 ) Amount allocated to 2016 and 2017 Loan based on modified terms 3,204 3,204 Amortization of premium related to convertible loans following 2018 modification (691 ) — $ 2,635 $ 3,204

Controlling Shareholder

Controlling Shareholder	12 Months Ended
	Dec. 31, 2018
Controlling Shareholder [Abstract]
CONTROLLING SHAREHOLDER	NOTE 9:- CONTROLLING SHAREHOLDER a. On November 15, 2016, Wize Israel’s Board of Directors (after receiving the approval of the Audit Committee on November 14, 2016) approved the receipt of a short-term bridge loan (“Loan”) in amount of NIS 250,000 (approximately $65 according to an exchange rate as of November 15, 2016) from Ridge. The Loan was received on November 21, 2016. The Loan was not linked to any index, had no collateral and bears yearly interest at the level of the interest rate of Israel State Bonds (0.1% as of December 31, 2016). The Loan’s repayment date was by the end of the first quarter of 2017 but may be extended from time to time at the Shareholder’s discretion. b. On December 25, 2016, Wize Israel’s Board of Directors (after receiving the approval of the Audit Committee on November 14, 2016) approved the receipt of an additional short-term bridge loan of NIS 300,000 (approximately $78 according to an exchange rate as of December 25, 2016) from the Shareholder under the same terms to those described above. NIS 200,000 (approximately $52 according to an exchange rate as of December 31, 2016) was received in December 2016 and the remaining amount of NIS 100,000 (approximately $27 according to an exchange rate as of December 31, 2016) was received after December 31, 2016. Accordingly, as of December 31, 2016, the total balance of the short-term bridge loans amounted to NIS 450,000 (approximately $117 according to an exchange rate as of December 31, 2016). c. On February 19, 2017, Wize Israel’s Board of Directors (after receiving the approval of the Audit Committee on February 16, 2017), approved the receipt of an additional short-term bridge loan of NIS 200,000 (approximately $55 according to the exchange rate as of February 19, 2017) from Ridge. The loan was not linked to any index, has no collateral and bears yearly interest at the level of the interest rate of Israel State Bonds. The loan’s repayment date shall be by the end of the first quarter of 2017 and will serve the Company in its current activity. Ridge may extend the loan’s redemption date from time to time at its discretion. On March 30, 2017, Wize Israel and Ridge agreed to convert the entire balance of the aforesaid bridge loans referenced above amounting to an aggregate amount of NIS 750,000 (approximately $206 according to the exchange rate as of March 31, 2017) as part of the 2017 Loan, the revised terms and conditions of which are described in Note 8a.

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2018
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 10:- TAXES ON INCOME a. Tax rates applicable to the Company: On December 22, 2017, the Tax Cuts and Jobs Act was enacted and made key changes to US tax law which include (i) establish a flat corporate income tax rate of 21% to replace current rates that range from 15% to 35% and eliminates the corporate alternative minimum tax; (ii) create a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time transition tax; (iv) create a “minimum tax” on certain foreign earnings and a new base erosion anti-abuse tax (BEAT) that subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum deduction for Net Operating Loss (NOL) carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer’s taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried forward indefinitely and generally repeals carrybacks; (vii) elimination of foreign tax credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi) repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions and credits, and adds other provisions that broaden the tax base. After the enactment of the Tax Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has calculated an estimate of the impact of the Tax Act in our year-end income tax provision in accordance with our understanding of the Tax Act and guidance available as of the date of this filing. The provisional amount related to the re-measurement of our net U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but which was fully and equally offset by a corresponding reduction in the Company’s valuation allowance. The effect of the change in federal corporate tax rate from 34% to 21% is subject to change based on resolution of estimates used in determining the amounts of deferred tax assets and liabilities that were re-measured. The change in U.S tax law has no impact on the consolidated financial statements. b. Tax rates applicable to Wize Israel and OcuWize: 1. Taxable income of the Subsidiary is subject to the Israeli Corporate tax rate which was 23% and 24% in 2018 and 2017 respectively. 2. In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), a reduction of the corporate tax rate in 2017 from 25% to 24%, and in 2018 and thereafter from 24% to 23%. The change in Israeli tax law has no impact on the consolidated financial statements. c. Net operating loss carry forward: As of December 31, 2018, the Company has net operating loss carry forwards for federal income tax purposes of approximately $3,811. The application of the net operating loss carry forwards is limited due to IRC section 382 limitation, the annual net operating loss carry forward (pre merger, approximately $2,734) is limited to $10.965 per year. The balance as of December 31, 2018 of the net operating loss carry forwards of approximately $1,077 is available in full. The balance as of December 31, 2018 of the net operating loss carry forwards of approximately $1,100 thousands is available in full. As of December 31, 2018, the Company’s subsidiaries, Wize Israel and OcuWize have accumulated losses for tax purposes in the amount of approximately $7,980 and $1,050 respectively, which may be carried forward and offset against taxable income in the future for an indefinite period in Israel. d. As of December 31, 2018, Wize Israel’s 2012 tax assessment was considered final. OcuWize has not received final tax assessment since its inception. e. Loss before taxes on income consists of the following: December 31, 2018 2017 Domestic $ (1,810) $ (2) Foreign (*) (1,469) (2,964) $ (3,279) $ (2,966) (*) Relates to Wize Israel. f. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: December 31, 2018 2017 Deferred tax assets: Operating loss carry forward $ 2,097 $ 1,688 Reserves and allowances 6 8 Research and development 136 89 Net deferred tax asset before valuation allowance 2,239 1,785 Valuation allowance (2,239 ) (1,785 ) Net deferred tax asset $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance at December 31, 2018 and 2017. g. Below is the reconciliation between the “theoretical” income tax expense or benefit, assuming that all the income was taxed at the regular tax rate applicable to companies in Israel and the taxes recorded in the statements of comprehensive loss in the reporting year: Year ended December 31, 2018 2017 Loss before taxes on income, as reported in the statements of comprehensive loss (3,279 ) (2,966 ) Theoretical tax benefit on this loss 689 716 Expenses not deductible for tax purposes (72 ) (51 ) Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized (617 ) (665 ) Tax benefit - -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11:- COMMITMENTS AND CONTINGENCIES a. Litigation From April 2015 to September 2015, Wize Israel and its directors who were also employees of Wize Israel received a number of letters from Go D.M. Investments Ltd (“Go D.M.”), an Israeli public company, engaged at the time in the field of repositioning of drugs, regarding its claims on various issues. On January 16, 2017, a settlement was signed between Go D.M. and certain parties related to the abovementioned litigation. On January 19, 2017, the Settlement was submitted to the Tel Aviv District Court for approval. On the same date, the Court ruled that the Settlement would be given the force of a legal ruling subject to meeting the preconditions as per the Settlement, including the Court’s approval of the arrangement in accordance with Section 350 of the Companies Law, 1999, and by February 21, 2017 the parties will update the Court on compliance with these conditions, and in the event that this takes place, the Settlement will be given the force of a legal ruling. On March 26, 2017, the parties entered into settlement agreement pursuant to which it was agreed on final, full and absolute waiver of any claims, suits and demands by the parties for legal proceedings and/or by anyone operating on their behalf (including subsidiaries, controlling shareholders and interested parties, executives and officers, directors). b. Agreements 1. Starting November 22, 2018, the Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period of 12 months with an option to extend the lease period for additional 12 months. 2. For the Company’s engagement in a License Agreement to market a drug and amendment to such an agreement, see also Note 5 above. 3. On June 19, 2017 (the “Effective Date”), Wize Israel entered into a finder’s fee agreement with a service provider (through his wholly owned company), who is also a director of the Company (the “Vendor”), pursuant to which the Vendor is entitle to receive a royalty rate of 5% on all of Wize Israel’s revenues to the extent such revenues are earned from relationships initiated by the Vendor and agreed to by Wize Israel. The term of the agreement is for 12 months unless earlier terminated. Either party may terminate upon 21 days’ notice. The service provider will be entitled to the finder fee of 5% even if the agreement will be terminated. The Vendor introduced Wize Israel and the Company to the Chinese Distributor (see also Note 5). During the period commencing the Effective Date and ended December 31, 2018, the vendor has not earned any royalties, and the Company has no obligation to pay any royalties.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2018
Stockholders’ Equity (Deficit) [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 12:- STOCKHOLDERS’ EQUITY (DEFICIT) a. The Common Stock confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation. b. On June 23, 2017, Wize Israel entered into a Private Placement Agreement (the “2017 PIPE Agreements”) with each of Eliahu Peretz (“Peretz”), Yaacov Zrachia (“Zrachia”), Simcha Sadan (“Sadan”) and Jonathan Brian Rubini (“Rubini”, and together with Peretz, Zrachia and Sadan, the “2017 PIPE Investors”). Pursuant to the 2017 PIPE Agreements, the 2017 PIPE Investors agreed to invest a total of NIS 3,490,000 (approximately $966) in exchange for a total of 860,987 ordinary shares of Wize Israel (the “2017 PIPE”), at a price per share of NIS 4.05 (approximately $1.15), with Peretz undertaking to invest NIS 490,000 (approximately $139 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 120,884 ordinary shares of Wize Israel (the “Peretz Investment”) and each of Zrachia, Sadan and Rubini (the “Other Investors”) undertaking to invest NIS 1,000,000 (approximately $282 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 246,701 ordinary shares of Wize Israel each (together, the “Other Investments”). Subject to the Closing Date of the Merger, Wize Israel also undertook to cause the Company to grant warrants to each of the 2017 PIPE Investors Warrants, with each Warrant being exercisable into one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), with a term of three years from the date of grant. c. According to the 2017 PIPE Agreements, the number of Warrants and the exercise price thereof will reflect, prior to giving effect to an adjustment based on the Exchange Ratio, (i) 30,625 warrants to Peretz and (ii) 62,500 warrants to each of the Other Investors, each warrant exercisable into one ordinary share of Wize Israel, at an exercise price of NIS 28.8 per share (approximately $8.4 according to the exchange rate as of December 31, 2017). According to the Exchange Ratio, Peretz was granted 126,928 Warrants exercisable into Common Stock and each of the Other Investors was granted 259,036 Warrants exercisable into Common Stock. Sadan’s commitment to provide his portion of the Other Financing was conditioned upon Wize Israel not raising more than NIS 3,500,000 (approximately $988 according to the exchange rate as of June 23, 2017) and not less than NIS 2,000,000 (approximately $565 according to the exchange rate as of June 23, 2017) in the 2017 PIPE, including the amount to be invested by Sadan. On June 22, 2017, Ridge provided notice to Wize Israel that it has waived its right to adjust the 2017 Loan Conversion Price in connection with the Peretz Investment. In July 2017, Wize Israel completed the Peretz Investment and Other Investments. However, Ridge did not waive its right to adjust the 2017 Loan Conversion Price in connection with the Other Investments. As a result of the Peretz Investment and Other Investments, the 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted from NIS 24.00 (approximately $6.72 according to the exchange rate as of June 23, 2017) to NIS 16.8 (approximately $4.8 according to the exchange rate as of June 23, 2017) and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment (see note 8 above), the aggregate principal amount of the 2017 Loan is $822,144 and the 2017 Loan Conversion Price was adjusted to $1.1112. During the period ended December 31, 2017, the investment amount of NIS 3,490,000 (approximately $1 million according to the exchange rate as of December 31, 2017) from Peretz Investment and Other Investments has been received and the Company issued a total of 860,987 ordinary shares and the warrants described above. d. On December 11, 2017, the Company announced a notice of special meeting of stockholders, according to which, a special meeting of the stockholders was held on February 19, 2018, for the purpose of considering to grant the Company’s Board of Directors the authority, in its sole direction, to approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200. e. On February 19, 2018, the stockholders of the Company approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200 at any time prior to February 19, 2019, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion. On February 22, 2018, the Company’s Board of Directors approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of 1-for-24 (“Reverse Stock Split”). For accounting purposes, all share and per share amounts for Common Stock, warrants stock, options stock and loss per share amounts reflect the Reverse Stock Split for all periods presented in these Financial Statements. Any fractional shares that resulted from the Reverse Stock Split were rounded up to the nearest whole share. f. On February 28, 2018, the Company received notices from existing stockholders and lenders to exercise 2016 Investment Right and 2017 Investment Rights and warrants issued in a private placement of Wize Israel that was completed in July and August 2017 (the “PIPE Warrants”) to purchase an aggregate of 788,658 shares of Common Stock. During 2018, the Company received the aggregate exercise price of approximately $1,145 and issued 788,658 shares of Common Stock as follows: 1. 144,168 PIPE warrants were exercised into 144,168 shares of common stock by certain stockholder. The aggregate exercise price amounted to approximately $292 was received in cash. As of December 31, 2018, 759,871 PIPE warrants remain outstanding. 2. Certain holders of the 2016 Investment Right and 2017 Investment Right exercised approximately $853 of their right and invested a total amount of $853 for 217,442 and 427,048 respectively, shares of common stock ($1.308 and $1.332 per share, respectively). As of December 31, 2018, the remaining 2016 Investment Right and 2017 Investment Rights amount to approximately $1,176. g. In April and June 2018, the Company issued 24,306 shares of Common Stock to two of its service providers in exchange for their services provided in 2018. The Company recognized an amount of $126 in 2018. h. On May 10, 2018, the Company filed an amendment to the S-1 Registration Statement, for the purpose of registering (i) 922,330 shares of Common Stock that were outstanding as of that date; and (ii) 338,945 shares of Common Stock which are issuable upon conversion of the 2016 Loan and/or the 2017 Loan. On July 12, 2018, the S-1 Registration Statement was declared effective by the SEC. i. In July 2018, the Company issued 67,778 shares of Common Stock to certain service providers in exchange for their services provided in 2018. The Company recognized an amount of $381 in its financial statements for year ended December 31, 2018. j. On October 22, 2018, The Company entered into a securities purchase agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company sold to the investors, and the investors purchased from the Company, in a private placement, an aggregate of (i) 3,100,000 shares of common stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of common stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also issued to the investors Series A warrants (the “Series A Warrants”) to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)), and Series B warrants (the “Series B Warrants, and together with the Series A Warrants, the “Warrants”), to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants have an exercise price of $1.10 per share, and the Series B Warrants have an exercise price of $1.00 per share. The investors under the Purchase Agreement include prior investors in the Company and a lender to the Company. The Series A Warrants have a term of 5 years from issuance, and the Series B Warrants will have a term that expires 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) has occurred, the expiration date of the Series B Warrants will be extended by one day. In the event that, during the period commencing upon execution of the Purchase Agreement, and expiring on the trading day immediately following the date that the Company has raised, beginning after the issuance date of the Warrants, at least $10 million in gross proceeds from the issuance of the Company’s securities, the Company issues or sells common stock (or securities convertible into or exercisable into common stock) at a purchase price (or conversion or exercise price, as applicable) lower than the exercise price of the Warrants, than the exercise price of the Warrants will be reduced to such lower price, subject to certain exceptions. Pursuant to the Purchase Agreement, the Company granted to the investors thereunder, for a period of three years from the closing date of the Purchase Agreement, a right of participation of up to an aggregate of 35% in any subsequent offering of the Company, subject to certain exceptions. The Warrants are exercisable on a cashless basis in the event that, six months after the closing of the Purchase Agreement, there is not an effective registration statement for the resale of the shares underlying the Warrants. The Warrants may not be exercised to the extent such exercise would cause the holder to beneficially own more than 4.99% (or 9.99%, at the election of the investor) of the Company’s outstanding common stock. Pursuant to the Purchase Agreement, the Company agreed that it will not, for a period commencing upon the closing of the Purchase Agreement, until the earlier of (i) 150 days following the date that all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, (ii) six months after the date that a non-affiliate investor under the Purchase Agreement may first sell securities purchased thereunder under Rule 144, (iii) 120 days following the listing of the common stock on a Qualified Market (as defined below) and (iv) the first trading day that the weighted average price of the common stock exceeds $5.00 per share for 10 consecutive trading days occurring after the date that a registration statement covering the resale of all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, offer or sell any common stock (or securities convertible into or exercisable into common stock), or file any registration statement, other than pursuant to the Registration Rights Agreement or on Form S-8, subject to certain exceptions. In connection with the Purchase Agreement, on October 22, 2018, the Company filed a Certificate of Designations of Series A Preferred Stock (the “Series A Certificate of Designations”) with the Secretary of State of Delaware. Pursuant to the Series A Certificate of Designations, the Company designated 1,350 shares of preferred stock as Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1,000 per share and is convertible into shares of common stock in an amount determined by dividing the stated value of $1,000 by the conversion price of $1.00, such that each share of Series A Preferred Stock is convertible into 1,000 shares of common stock. The Series A Preferred Stock may not be converted into common stock to the extent such conversion would cause the holder to beneficially own more than 4.99% (or 9.99%, at the election of the investor) of the Company’s outstanding common stock. The Series A Preferred Stock is entitled to dividends on an as-converted basis with the common stock. The Series A Preferred Stock votes with the common stock on an as-converted basis, subject to the beneficial ownership limitation. The Series A Preferred Stock are not entitled to any redemption amount. The Company will be obligated to pay liquidated damages to the investors if the Company fails to file the resale registration statement when required, fails to cause the Registration Statement to be declared effective by the SEC when required, fails to maintain the Registration Statement and upon the occurrence of certain other events. The Company shall pay to each investor cash equal to 2% of such investor’s total purchase price on the dates of each deficiency and on the 30th day after such deficiencies until such deficiencies are cured, up to a maximum of 10% of the purchase price. The Company received notice of effectiveness on the resale registration statement on December 4, 2018. The Company engaged ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as the placement agent for the private placement, pursuant to a placement agency agreement between the Company and ThinkEquity (the “Placement Agency Agreement”). The Company paid ThinkEquity a fee equal to 8% of the gross proceeds, excluding proceeds received from certain investors for its services as placement agent, and issued to ThinkEquity or its designees warrants to purchase 267,000 shares of common stock (equal to 6% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). Such warrants have an exercise price of $1.00 per share and have the same terms as the Series A Warrants issued to the investors under the purchase agreement. The Company also paid to ThinkEquity a non-accountable expense allowance of $30 and reimbursed ThinkEquity for its legal expenses in connection with the offering in the amount of $50. The Company granted to ThinkEquity a right of first refusal for a period of nine months following the closing of the offering, to act as sole financial advisor, sole investment banker, sole book-runner, and/or sole placement agent, for each and every future public and private equity and debt offering of the Company during such period, on terms and conditions customary to ThinkEquity. The Company also paid Mesodi Consultation & Investments, Ltd. (“Mesodi”) a fee of $89 and issued to Mesodi warrants to purchase 89,000 shares of common stock. Such warrants have the same terms as the Warrants issued to the investors, in connection with the private placement. In connection with the Purchase Agreement, on October 19, 2018 the Company and its wholly-owned subsidiary Wize Pharma Ltd. (“Wize Israel”) entered into an amendment to the existing convertible loan (the “Amendment”). Pursuant to Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date. In accordance with ASU 2017-11, which was early applied by the Company, the Company concluded that the Series A Convertible Preferred Stock and related Warrants meet the requirements for equity classification since they are considered to be indexed to the Company’s common stock and as they meet all other equity classification criteria described in ASC 815-40-25. k. In December 2018, the Company issued 440,000 shares of Common Stock to certain investors in exchange for conversion of 440 Preferred A stock, which was in accordance with terms of the purchase agreement. l. In December 2018, the Company issued 55,000 shares of Common Stock to certain service providers in exchange for their services to be provided in 2019. The fair value of the stock issued amounts to $54 and was recorded under other current assets. m. Stock based-compensation: The 2012 Plan In 2012, the Company’s Board of Directors approved the adoption of the 2012 Stock Incentive Plan (the “2012 Plan”). An Israeli annex was subsequently adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section 102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees and consultants, stock options, restricted stocks and Restricted Stock Units (“RSUs”) of the Company. Each Stock option granted shall be exercisable at such times and terms and conditions as the Company’s Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, the Company reserved for issuance 45,370 shares of Common Stock, $0.001 par value each. As of December 31, 2018, the Company has 40,474 shares of Common Stock available for future grant under the 2012 Plan. As of December 31, 2018, under the 2012 Plan, the Company had options exercisable into 4,896 shares of Common Stock outstanding and exercisable. The 2018 Plan On February 22, 2018, the Company’s Board of Directors approved the adoption of the 2018 Stock Incentive Plan (the “2018 Plan”), including an Israeli annex to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance. Under the 2018 Plan, the Company may grant its employees, directors, consultants and/or contractors’ stock options, shares of Common Stock, restricted stock and restricted stock units of the Company. The Compensation Committee of the Board of Directors is currently serving as the administrator of the 2018 Plan. Each stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments over the three - year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will be seven years. The exercise price per share subject to each option will be determined by the administrator, subject to applicable laws and to guidelines adopted by the Board of Directors from time to time. In the event the exercise price is not determined by the administrator, the exercise price of an option will be equal to the closing stock price of the Common Stock on the last trading day prior to the date of grant. Upon the adoption of the 2018 Plan, the Company’s Board of Directors reserved for issuance 2,500,000 shares of Common Stock. In addition, the Board of Directors approved to increase the number of shares issuable under the Plan on the first day of each fiscal year beginning with the 2019 fiscal year, by an amount equal to the lesser of (i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year. Through December 31, 2018, the Company has granted 255,000 options to directors, officers and consultants. Grants under 2018 plan n. On April 4, 2018, the Company granted to its officers, directors and a consultant, 131,200 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company’s common stock on the date of issuance. The aggregate fair value of these restricted stock units issued was $471, and was recognized during the three months ended June 30, 2018. o. On April 4, 2018, the Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $295 during the year ended December 31, 2018. p. On August 15, 2018, the Company granted to its consultant options exercisable into 25,500 shares of Common Stock with an exercise price of $4.5 per share. The options will vest quarterly over a period of 36 months. The Company recognized $16 during the year ended December 31, 2018. Transactions related to the grant of options to employees and directors under the 2012 Plan during the year ended December 31, 2018, were as follows: As of December 31, 2018 and 2017 Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding at beginning of year 4,896 $ 190.8 4.86 Granted - - - Options outstanding and exercisable as of December 31, 2018 4,896 $ 190.8 4.11 Transactions related to the grant of options to employees and directors under the 2018 Plan during the year ended December 31, 2018, were as follows: As of December 31, 2018 Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2017 - $ - - Granted 255,000 $ 3.68 6.55 Options outstanding as of December 31, 2018 255,000 $ 3.68 6.55 Options exercisable as of December 31, 2018 38,246 $ 3.59 6.25 At December 31, 2018, there was $295 of total unrecognized compensation cost related to non-vested option grants that is expected to be recognized over a weighted-average period of 2.5 years. The intrinsic value of options outstanding and exercisable at December 31, 2018 was not significant. The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate of interest was based on the U.S. Treasury rates appropriate for the contractual term of the grant, expected volatility was calculated based on average volatility of the Company and five representative companies and expected term of stock-based grants of 7 years.

Selected Statements of Operatio

Selected Statements of Operations Data	12 Months Ended
	Dec. 31, 2018
Selected Statements of Operations Data [Abstract]
SELECTED STATEMENTS OF OPERATIONS DATA	NOTE 13:- SELECTED STATEMENTS OF OPERATIONS DATA a. General and administrative expenses: Year ended December 31, 2018 2017 Overseas travel $ 118 $ 72 Share-based payment 783 - Rent and office maintenance 46 53 Payroll and benefits 518 300 Professional services and consultation 1,051 472 Taxes and tolls 16 46 Director salary and insurance 191 63 Others 213 25 $ 2,936 $ 1,031 b. Financial expenses (income), net: Year ended December 31, 2018 2017 Financial income: Amortization of premium related to convertible loans $ (2,149 ) - Total finance income (2,149 ) - Financial expenses: Accrued interest on convertible loans 56 47 Change in fair value of marketable equity securities 33 - Amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for 2016 Loan - 1,122 Amortization of discount and exchange rate differences on license purchase obligation - 3 Bank commissions and exchange rates - 6 Change in the fair value of derivative liability for right to future investment - 246 Loss from extinguishment of convertible loans (Note 8) 1,709 61 Total financial expenses 1,798 1,485 Total financial expenses (income), net $ (351 ) $ 1,485

Related Parties Balances and Tr

Related Parties Balances and Transactions	12 Months Ended
	Dec. 31, 2018
Related Parties Balances and Transactions [Abstract]
RELATED PARTIES BALANCES AND TRANSACTIONS	NOTE 14:- RELATED PARTIES BALANCES AND TRANSACTIONS a. Balances with interested and related parties: December 31, 2018 2017 Other accounts payable $ 97 $ 54 Convertible Loans $ 2,590 $ 2,544 b. Transactions with interested and related parties: Year ended December 31, 2018 2017 Amounts charged to: General and administrative expenses $ 1,209 $ 263 Finance expenses, net (income) $ (306 ) $ 1,181

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15:- SUBSEQUENT EVENTS 1. On March 4, 2019, the Company and its wholly-owned subsidiary Wize Pharma Ltd. (“Wize Israel”) entered into an amendment to convertible loan agreements (the “Amendment”) with Rimon Gold Assets Ltd. (“Rimon Gold”), Ridge Valley Corporation (“Ridge Valley”), and Shimshon Fisher (“Fisher” and, together with Rimon Gold and Ridge Valley, the “Lenders”). Pursuant to the Amendment, the maturity date under the (i) convertible loan agreement between Wize Israel and Rimon Gold, dated March 20, 2016 (as amended, the “2016 Loan Agreement”), and (ii) convertible loan agreement, dated January 12, 2017 (as amended, the “2017 Loan Agreement”), among Wize Israel, Rimon Gold, and Ridge Valley, was extended to May 31, 2019 (as previously described under the 2018 Loan Modification) from March 4, 2019. The parties also agreed that the Lenders’ investment rights under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and the Lender’s investment rights under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from June 30, 2019 to November 30, 2019. 2. On February 7, 2019, the Company entered into a joint venture agreement with Cannabics Pharmaceuticals, Inc. (“Cannabics”). Pursuant to the agreement, the parties agreed to form a new joint venture company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions. The new company will initially be owned 50% each by the Company and Cannabics. Promptly following the effective date, the Company and Cannabics will work together to prepare a business plan for the new company. The initial board of directors of the new company will consist of three members, including one each appointed by the Company and Cannabics, and one industry expert recommended by the Company and approved by Cannabics. The initial officers of the Company will be Noam Danenberg (the Company’s chairman) and Eyal Barad (Cannabics’ chief executive officer), who will serve as co-chief executive offices. If the business plan is not approved by the Company and Cannabics by June 30, 2019, the joint venture agreement will then expire. The Company agreed to issue to Cannabics 900,000 shares of the Company’s common stock upon the effective date, and Cannabics agreed to issue to the Company 2,263,944 shares of Cannabics’ common stock, upon the effective date. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. On March 1, 2019, the Company’s joint venture agreement with Cannabics Pharmaceuticals, Inc. (“Cannabics”) became effective following receipt of an opinion, within 30 days from execution of the agreement, from a mutually selected third party describing the regulatory pathway for eye drops containing cannabinoids or cannabinoid strings. Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000 shares of its common stock and Cannabics issued to the Company 2,263,944 shares of Cannabics’ common stock. 3. On March 31, 2019, following recommendation of the compensation committee which was held on February 20, 2019, the Company’s board of directors approved the following: 1. To grant to each its directors 100,000 RSU’s. The RSU’s will vest quarterly over a period of 24 months. 2. To grant to each its officers 140,000 RSU’s. The RSU’s will vest quarterly over a period of 24 months.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Use of estimates in preparation of the Financial Statements:	a. Use of estimate in preparation of financial statements: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and freestanding financial instruments related to convertible loans and rights to future investment and the determination whether modification of terms of financial instruments is substantial.
Principles of consolidation	b. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated upon consolidation.
Functional currency	c. Functional currency: Prior to the Merger, as Wize Israel activities were conducted in Israel and most of its financing was denominated and determined in New Israel Shekels (NIS), management has determined that the functional currency of Wize Israel was NIS. Following to the Closing Date of the Merger, the Company aims to direct its main operations in the United States market. In addition, following to the Closing Date of the Merger, the current convertible loans which were previously denominated in NIS, were changed into U.S. dollars terms, including their principal and conversion price. Similarly, the Company issued warrants eligible for exercise for the Company’s shares of common stock at an exercise price denominated in U.S. dollars. Also, the management believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, as of that date, the functional currency of the Company was changed into the U.S. dollar. The reporting currency of the consolidated financial statements is U.S. dollars. Pre-merger, Wize Israel and OcuWize results were translated into U.S. dollars in accordance with the standards of the Financial Accounting Standards Board (“FASB”). Accordingly, assets and liabilities were translated from NIS to U.S. dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is different than the U.S. dollar) were reported in other comprehensive income and are reflected in equity, under “accumulated other comprehensive income (loss)”. As a result of adoption of ASU 2016-01, as discussed in note 2v, accumulated other comprehensive income as of December 31, 2018 consists solely of foreign currency translation adjustment. Balances denominated in, or linked to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. The following table presents data regarding the dollar exchange rate of relevant currencies: As of December 31, % of change 2018 2017 2018 2017 USD 1 = NIS 3.748 3.467 8.1 (9.8 )
Cash and cash equivalents	d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. For presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total amounts. December 31 2017 Cash and cash equivalents $ 215 Restricted cash 12 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 227 There were no restricted cash amounts as of December 31, 2018.
Restricted bank deposit	e. Restricted bank deposit: Restricted bank deposit is a deposit with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including accrued interest and represents cash which is used as collateral for Wize Israel’s credit card.
Marketable equity securities	f. Marketable equity securities: Until December 31, 2017, the Company’s investment in marketable equity securities was classified as available-for-sale carried at fair value based on the quoted market price, with unrealized gains and losses reported as a separate component of stockholders’ deficit under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. The Company accounted for these marketable equity securities as available-for-sale carried at fair value since these marketable equity securities were considered available to be converted into cash to fund Company’s current operations. The Company was required to recognize an impairment charge when a decline in the fair value of its investments in securities was below the cost basis of such securities and was determined to be other than temporary. Factors considered in making such a determination included the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company’s intent to sell. For securities that were deemed other-than-temporarily impaired, an impairment was recognized as the difference between the cost basis of the impaired equity security and the fair value on the measurement date, as part of financial income, net in the statement of comprehensive loss. The fair value on measurement date was considered the equity security’s new cost basis. As of December 2017, the Company has not recorded loss from impairment. Commencing January 1, 2018, following the effective date of ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” (ASU 2016-01), the Company’s investment in marketable equity securities which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value with any changes in fair value recognized periodically in net income.
Property and equipment, net:	g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and electronic equipment 33 Furniture and office equipment 10
Impairment of long-lived assets:	h. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360 “Property, plant and equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During the years ended December 31, 2018 and 2017, no impairment losses have been identified.
Research and development expenses:	i. Research and development expenses: Research and development expenses are charged to the statement of comprehensive loss as incurred. In-Process Research and Development assets (“IPR&D”), acquired in an asset acquisition (i.e. assets acquired outside a business combination transactions) that are to be used in a research and development project which are determined not to have an alternative future use are charged to expense at the acquisition date in accordance with ASC 730, “Research and Development”.
Severance pay	j. Severance pay: Wize Israel has two employee as of December 31, 2018 and 2017. Wize Israel’s liability for severance pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), pursuant to which all Wize Israel’s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee’s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2018 and 2017. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. Severance expenses for the years ended December 31, 2018 and 2017 amounted to $10 for both periods.
Income taxes	k. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2018 and 2017, no liability for unrecognized tax positions has been recognized.
Concentrations of credit risk	l. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted bank deposits. Cash and cash equivalents and restricted bank deposits are invested in major banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Convertible loans	m. Convertible loans: Allocation of proceeds: The proceeds received upon the original issuance of the 2016 Loan together with a freestanding derivative financial instrument (derivative liability for right to future investment) were allocated to the financial instruments issued based on the residual value method. The detachable derivative financial instrument related to the 2016 loan was recognized based on its fair value and the remaining amount of the proceeds was allocated to the 2016 Loan component. Beneficial Conversion Features (“BCF”): a. Upon initial recognition, the Company has considered the provisions of ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity”, and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, “Debt - Debt with Conversion and Other Options” which clarifies the accounting for instruments with BCF or contingently adjustable conversion ratios, and has applied the BCF guidance to determine whether the conversion feature is beneficial to the investor. The BCF was calculated by allocating the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative liability for future investment (see also Note 8)) included in the transaction, and by measuring the intrinsic value of the conversion option based on the effective conversion price as a result of the allocated proceeds. The intrinsic value of the conversion option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method. b. Upon initial recognition, the Company has considered the provisions of ASC 815-15, “Derivatives and Hedging - Embedded Derivatives” (“ASC 815-15”), and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, since its terms do not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash. Furthermore the Company applied ASC 470-20 which clarifies the accounting for instruments with BCF or contingently adjustable conversion ratios. Pursuant to ASC 470-20-30, the amount of the BCF with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion price (i.e. the entire proceeds received for the 2017 Loan) and the aggregate fair value of the common stock and other securities (which consist of the Investment Option) into which the 2017 Loan is convertible. As such difference was determined to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned to the BCF was limited to the amount of the entire proceeds. c. Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, “Debt – Debt with conversion and other options” to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following the extinguishment of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors. d. Modifications or exchanges Modifications to, or exchanges of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions of ASC 470-50, “Debt- Modification and Extinguishments”. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. Under ASC 470-50, modifications or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new debt and original instrument are substantially different. The instruments are considered “substantially different” when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the debt instruments are not considered to be substantially different, except in the following two circumstances (i) The transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the modification or exchange or (ii) The transaction adds a substantive conversion option or eliminates a conversion option that was substantive at the date of the modification or exchange. If the original and new debt instruments are considered as “substantially different”, the original debt is derecognized and the new debt is initially recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable. If a convertible debt instrument with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument. The gain or loss on the extinguishment of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the allocated reacquisition price. Modifications to, or exchanges of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments before and after the modification or exchange are substantially different. If the original and new equity instruments are considered as “substantially different”, the excess fair value of the allocated reacquisition price over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as a deemed dividend. Issuance costs of convertible loan: a. Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) are presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCF if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred. b. Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan also discussed in Note 8 (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.
Fair value of financial instruments	n. Fair value of financial instruments: ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the investments are categorized as Level 3. The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their fair value due to the short-term maturities of such instruments. Fair value of the marketable equity securities is determined based on a Level 1 input. Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Company would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency or stock prices, as applicable. The fair value measurement of the derivative liability for right to future investment (which were classified to equity during 2017) and the financial instruments included under 2017 Loan and 2016 Loan (see note 8) are classified within Level 3. Following each of the modifications described in Note 8, Wize Israel’s management engaged an external appraiser that measured the fair value of the financial instruments exchanged or modified, as further described in Note 8 and in the following paragraph. The following tabular presentation reflects the components of the derivative liability associated with rights to future investment during the year ended December 31, 2017: Fair value Balance at December 31, 2016 $ 34 Change in the fair value of derivative liability 246 Reclassification of derivative liability into equity (*) (280 ) Balance at December 31, 2017 $ - (*) Upon the December 2017 modification, and in accordance with ASC 815-40 “Derivatives and Hedging, Contracts in Entity’s Own Equity”, it was determined that the right to future investment is eligible to be considered as indexed to the Company’s own stock. Accordingly, the fair value of the Right of Future Investment immediately prior to the Modification Date (December 2017) which amounted to NIS 1,042,000 (approximately $280 according to the exchange rate as of the Modification Date) was reclassified from a derivative liability to additional paid-in capital.
Legal and other contingencies	o. Legal and other contingencies: The Company accounts for its contingent liabilities in accordance with ASC 450 “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2018, the Company is not a party to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Treasury shares	p. Treasury shares: Shares held by the Company are presented as a reduction of equity, at their cost to the Company as treasury stock, until such shares are retired and removed from the account.
Derivatives	q. Derivatives: The Company applies the provisions of ASC Topic 815, “Derivatives and Hedging” pursuant to which all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. As of December 31, 2016, the balance of derivative instruments consisted of derivative liability for right to future investment in an amount of $34 (see also n. above and r. below), and is stated at fair value. As of December 31, 2018 and 2017, there were no financial instruments required to be accounted as derivatives (see also n. above and r. below). During the years ended December 31, 2018 and 2017, the Company did not designate any financial instruments for hedging purposes.
Derivative liability for right to future investment	r. Derivative liability for right to future investment: Upon initial recognition, the Company reviewed the terms of such obligation and determined that it is not eligible to be classified as a component of permanent equity, as such instrument permitted the holder to receive a variable number of shares of common stock upon exercise, by investment of cash amount that will be determined at the discretion of the holder (up to a pre-determined cap). Accordingly, such financial instrument was accounted for as a derivative liability and as such was measured upon initial recognition and re-measured at subsequent reporting periods at fair value. Changes in the fair value were recorded in the consolidated statement of comprehensive loss within the caption “financial expense, net”. Upon the December 2017 modification, and in accordance with ASC 815-40 “Derivatives and Hedging, Contracts in Entity’s Own Equity”, it was determined that the right to future investment, eligible to be considered as indexed to the Company’s own stock and as a result the derivative liability for right to future investment was reclassified into additional paid-in capital (see also Note 8).
Series A Warrants with Down-Round Protection	s. Series A Warrants with Down-Round Protection Commencing January 1, 2018 and following the early adoption of Accounting Standard Update (ASU) No. 2017-11, “I. Accounting for certain financial instruments with Down Round Features” (ASU 2017-11) as described in Note 2.t, the Company disregard certain down-round features when assessing whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification. Based on its evaluation, management has determined that Series A Warrants (the “Warrants”) that were issued on October 2018, as part of a private placement, as described in Note 12J, which include a down-round protection that would adjust the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, are eligible for equity classification. In accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when the exercise price of the Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation. During the period from issuance of the Warrants and throughout December 31, 2018, there were no events that require a downward adjustment of the current exercise price of the Warrants.
Basic and diluted loss per share	t. Basic and diluted loss per share: Basic loss per share is computed by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of common stock outstanding during the period. Securities that may participate in dividends with the common stock (such as the convertible Series A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of net loss, such participating securities are included in the computation, since the holders of such securities have a contractual obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares). In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and rights for future investment issued or granted using the “treasury stock method” and upon the conversion of 2017 Loan and 2016 Loan using the “if-converted method”, if the effect of each of such financial instruments is dilutive. For the years ended December 31, 2018 and 2017, all outstanding stock options and other convertible instruments have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2018 and 2017, is as follows: Year ended 2018 2017 Numerator: Net loss $ (3,279 ) $ (2,966 ) Add: Loss attributed to preferred stock (*) 147 - Less: Deemed dividend with respect to right for future investment $ (292 ) $ (3 ) Net loss applicable to stockholders of Common Stock $ (3,424 ) $ (2,969 ) Denominator: Shares of common stock used in computing basic and diluted net loss per share 5,649,262 3,438,842 Net loss per share of Common stock, basic and diluted $ (0.61 ) $ (0.86 ) (*) During the year ended December 31, 2018 the Company issued preferred stock as part of the October 2018 transaction. These preferred shares are participating securities as described in Note 12.j. During the years ended December 31, 2018 and 2017 there were no other potentially dilutive instruments.
Accumulated other comprehensive loss	u. Accumulated other comprehensive loss: Accumulated other comprehensive loss, presented in stockholders’ deficit, includes (i) gains and losses that were incurred from the translation of the pre-merger results of Wize Israel and OcuWize to the reporting currency (see also Note 2c) and (ii) unrealized gain from the change in the fair value of marketable equity securities that were classified as available-for-sale until December 31, 2017. The components of accumulated other comprehensive income (loss) as of December 31, 2017 and 2018 were as follows: Total accumulated other comprehensive income (loss) Balance at January 1, 2017 $ (47 ) Cumulative effect adjustment as a result from transition to ASU 2016-01 (26 ) Balance at December 31, 2018 $ (73 )
Stock-based compensation	v. Stock-based compensation: Stock-based compensation to employees is accounted for in accordance with ASC 718, “Compensation - Stock Compensation” (“ASC 718”), which requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period. Stock-based compensation expense is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The fair value of stock options granted to Wize Israel employees was estimated using the binominal model, which requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon historical volatilities of Wize Israel on a weekly basis since the marketability of Wize Israel is less than the expected option term. The expected option term represents the period that Wize Israel’s stock options are expected to be outstanding and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The expected dividend yield assumption is based on Wize Israel’s historical experience and expectation of no future dividend payouts. Wize Israel has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future. Until December 31, 2017, ASC 505-50, “Equity-Based Payments to Non-Employees” (“ASC 505”) provisions were applied with respect to options and warrants issued to non-employees which requires the use of option valuation models to measure the fair value of the options and warrants at the grant date, and at the end of each accounting period between the grant date and the final measurement date. Following the adoption of ASU2018-07 all equity-classified nonemployee share-based payment awards granted during 2018 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue. Upon the Closing Date of the Merger (see also Note 1d), all the outstanding options under 2015 Plan of Wize Israel were cancelled.
Disclosure of new Standards in the period	w. Disclosure of new accounting standards ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” Commencing January 2018, the Company applied ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” (ASU 2016-01). ASU 2016-01 amends the guidance on the classification and measurement of financial instruments. Among others, ASU 2016-01 requires that equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) will be measured at fair value with changes in fair value recognized in net income. Also, ASU 2016-01 simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment and requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. ASU 2016-01 requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure a liability at fair value in accordance with the fair value option for financial instruments. ASU 2016-01 also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or in the accompanying notes to the financial statements. For public business entities, the amendments of ASU 2016-01 became effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU 2016-01 requires that its amendment will be applied using a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption . Following the adoption of ASU 2016-01, the Company reclassified unrealized gains and losses amounts related to its investment in marketable equity securities that previously were classified as available-for-sale securities from accumulated other comprehensive income to accumulated deficit on January 1, 2018. Following the adoption, such investment is accounted for at fair value and the changes in fair value are recognized in net income or loss. ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07). ASU 2018-07 aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 will be measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the goods has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based payment awards will be measured at the grant date (the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award). With respect to awards with performance conditions, ASU 2018-07 concludes that, consistent with the accounting for employee share-based payment awards, an entity will consider the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. ASU 2018-07 also requires that the classification of equity classified nonemployee share-based payment awards will continue to be subject to the requirements of Topic 718 unless the award was modified after the goods has been delivered, the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing goods or services. This eliminates the requirement to reassess classification of such awards upon vesting. ASU 2018-07 is effective for public business entities in annual periods beginning after 15 December 2018, and interim periods within those years. Early adoption is permitted, including in an interim period, but not before an entity adopts the new revenue recognition guidance (which became effective for the Company in its interim financial statements for 2018). An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity-classified awards for which a measurement date has not been established, through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these nonemployee awards at fair value as of the adoption date. The Company has elected to early apply ASU 2018-07 in its interim financial statements for the interim period ended September 2018. However, as there are no liability-classified awards and as there were no equity-classified awards for which a measurement date has not been established as of January 1, 2018 (the beginning of the fiscal year of adoption), the adoption did not have significant effect on the financial statements. Also, as a result of the adoption all equity-classified nonemployee share-based payment awards granted during 2018 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.
Recent Accounting Pronouncements not adopted yet	x. Recent Accounting Pronouncements not adopted yet In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize their leases contracts as assets and liabilities in the financial statements. Furthermore, the ASU requires the Company to continue recognizing expenses but recognize expenses on their income statements in a manner similar to current lease accounting. The amendments in this ASU are effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that applies the new lease requirements through a cumulative-effect adjustment in the period of adoption. Effective January 1, 2019, the Company intends to adopt the new lease accounting standard using the modified retrospective transition option of applying the new standard at the adoption date. The Company intends to elect the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification. The Company has completed an initial assessment of the potential impact on its consolidated financial. The actual impact of applying ASU 2016-02 will not be with a significant effect on Company’s consolidated financial statements

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Schedule of exchange rate of relevant currencies	As of December 31, % of change 2018 2017 2018 2017 USD 1 = NIS 3.748 3.467 8.1 (9.8 )
Summary of restrict cash balances are included with cash and cash equivalents	December 31 2017 Cash and cash equivalents $ 215 Restricted cash 12 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 227
Schedule of straight-line method over the estimated useful lives	% Computers and electronic equipment 33 Furniture and office equipment 10
Schedule of derivative liability	Fair value Balance at December 31, 2016 $ 34 Change in the fair value of derivative liability 246 Reclassification of derivative liability into equity (*) (280 ) Balance at December 31, 2017 $ - (*) Upon the December 2017 modification, and in accordance with ASC 815-40 “Derivatives and Hedging, Contracts in Entity’s Own Equity”, it was determined that the right to future investment is eligible to be considered as indexed to the Company’s own stock. Accordingly, the fair value of the Right of Future Investment immediately prior to the Modification Date (December 2017) which amounted to NIS 1,042,000 (approximately $280 according to the exchange rate as of the Modification Date) was reclassified from a derivative liability to additional paid-in capital.
Schedule computing basic and diluted net loss per share	Year ended 2018 2017 Numerator: Net loss $ (3,279 ) $ (2,966 ) Add: Loss attributed to preferred stock (*) 147 - Less: Deemed dividend with respect to right for future investment $ (292 ) $ (3 ) Net loss applicable to stockholders of Common Stock $ (3,424 ) $ (2,969 ) Denominator: Shares of common stock used in computing basic and diluted net loss per share 5,649,262 3,438,842 Net loss per share of Common stock, basic and diluted $ (0.61 ) $ (0.86 ) (*) During the year ended December 31, 2018 the Company issued preferred stock as part of the October 2018 transaction. These preferred shares are participating securities as described in Note 12.j. During the years ended December 31, 2018 and 2017 there were no other potentially dilutive instruments.
Schedule of accumulated other comprehensive income (loss)	Total accumulated other comprehensive income (loss) Balance at January 1, 2017 $ (47 ) Cumulative effect adjustment as a result from transition to ASU 2016-01 (26 ) Balance at December 31, 2018 $ (73 )

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Other Current Assets [Abstract]
Summary of other current assets	December 31, 2018 2017 Prepaid expenses $ 97 $ 3 Governmental authorities 75 37 Other 8 - $ 180 $ 40

License Purchase Obligation (Ta

License Purchase Obligation (Tables)	12 Months Ended
	Dec. 31, 2018
License Purchase Obligation [Abstract]
Schedule of repayment dates of the remaining minimal commitment on the financial liability	As of December 31, 2018 2017 Repayment dates: January 1, 2018 $ - $ 250 January 1, 2019 250 - Remaining balance 250 250 Current liability 250 250 Non-current liability - - Total $ 250 $ 250

Other Accounts Payable (Tables)

Other Accounts Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Other Accounts Payable [Abstract]
Schedule of other accounts payable	December 31, 2018 2017 Employees and payroll accruals (*) $ 130 $ 101 Accrued expenses 142 95 $ 272 $ 196 (*) As of December 31, 2018 and 2017, most of the sum refers to a debt to the Company’s Chief Executive Officer, with whom the Company had reached an agreement regarding postponing the payment date. The debt is expected to be paid in the foreseeable future.

Convertible Loans (Tables)

Convertible Loans (Tables)	12 Months Ended
	Dec. 31, 2018
Convertible Loans [Abstract]
Schedule of 2017 loan and 2016 loan that were amended to be denominated in U.S. dollars instead of NIS	2017 Loan 2016 Loan Aggregate principal amount $ (*) 822 $ 531 Conversion price per Company’s share $ 1.1112 $ 0.9768 Aggregate maximum of Right to Future Investment $ (**) 1,233 $ 797 Exercise Price of Right to Future Investment $ 1.332 $ 1.308 (*) Principal loan amount of $274 for each of the three 2017 Lenders. (**) Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders.
Schedule of roll forward of 2017 loan and 2016 loan	December 31, 2018 2017 Opening balance $ 3,204 $ 289 Proceeds from issuance of 2017 loan, net of issuance cost — 811 Recognition of BCF as a discount of 2017 Loan — (811 ) Amortization of premium related to convertible loans prior to 2018 modification (1,458 ) — Amortization of discounts resulting from BCF and derivative liability and debt issuance costs related to 2017 Loan and 2016 Loan — 1,122 Accrued interest on 2017 Loan and 2016 Loan 56 47 Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments (1,680 ) (1,458 ) Amount allocated to 2016 and 2017 Loan based on modified terms 3,204 3,204 Amortization of premium related to convertible loans following 2018 modification (691 ) — $ 2,635 $ 3,204

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2018
Taxes on Income [Abstract]
Schedule of loss before taxes on income	December 31, 2018 2017 Domestic $ (1,810) $ (2) Foreign (*) (1,469) (2,964) $ (3,279) $ (2,966) (*) Relates to Wize Israel.
Schedule of deferred income taxes	December 31, 2018 2017 Deferred tax assets: Operating loss carry forward $ 2,097 $ 1,688 Reserves and allowances 6 8 Research and development 136 89 Net deferred tax asset before valuation allowance 2,239 1,785 Valuation allowance (2,239 ) (1,785 ) Net deferred tax asset $ - $ -
Schedule of income tax expense or benefit	Year ended December 31, 2018 2017 Loss before taxes on income, as reported in the statements of comprehensive loss (3,279 ) (2,966 ) Theoretical tax benefit on this loss 689 716 Expenses not deductible for tax purposes (72 ) (51 ) Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized (617 ) (665 ) Tax benefit - -

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2018
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of grant of options to employees and directors	December 31, 2018 Opening balance - Granted 131,200 Outstanding as of December 31, 2018 131,200
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of grant of options to employees and directors	As of December 31, 2018 and 2017 Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding at beginning of year 4,896 $ 190.8 4.86 Granted - - - Options outstanding and exercisable as of December 31, 2018 4,896 $ 190.8 4.11
2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of grant of options to employees and directors	As of December 31, 2018 Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2017 - $ - - Granted 255,000 $ 3.68 6.55 Options outstanding as of December 31, 2018 255,000 $ 3.68 6.55 Options exercisable as of December 31, 2018 38,246 $ 3.59 6.25

Selected Statements of Operat_2

Selected Statements of Operations Data (Tables)	12 Months Ended
	Dec. 31, 2018
Selected Statements of Operations Data [Abstract]
Schedule of general and administrative expenses	Year ended December 31, 2018 2017 Overseas travel $ 118 $ 72 Share-based payment 783 - Rent and office maintenance 46 53 Payroll and benefits 518 300 Professional services and consultation 1,051 472 Taxes and tolls 16 46 Director salary and insurance 191 63 Others 213 25 $ 2,936 $ 1,031
Schedule of financing expenses net	Year ended December 31, 2018 2017 Financial income: Amortization of premium related to convertible loans $ (2,149 ) - Total finance income (2,149 ) - Financial expenses: Accrued interest on convertible loans 56 47 Change in fair value of marketable equity securities 33 - Amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for 2016 Loan - 1,122 Amortization of discount and exchange rate differences on license purchase obligation - 3 Bank commissions and exchange rates - 6 Change in the fair value of derivative liability for right to future investment - 246 Loss from extinguishment of convertible loans (Note 8) 1,709 61 Total financial expenses 1,798 1,485 Total financial expenses (income), net $ (351 ) $ 1,485

Related Parties Balances and _2

Related Parties Balances and Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Parties Balances and Transactions [Abstract]
Schedule of interested and related parties	December 31, 2018 2017 Other accounts payable $ 97 $ 54 Convertible Loans $ 2,590 $ 2,544
Schedule of transactions with interested and related parties	Year ended December 31, 2018 2017 Amounts charged to: General and administrative expenses $ 1,209 $ 263 Finance expenses, net (income) $ (306 ) $ 1,181

General (Details)

General (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	May 31, 2015
General (Textual)
Accumulated deficit		$ (29,997)	$ (26,452)
Royalty payments	$ 185	250
Sale of price per unit					$ 0.60
Stockholders' deficit		212	$ (3,098)	$ (831)
Aggregate principal amount		$ 1,353
Merger [Member]
General (Textual)
Reverse stock split, description		The Closing Date of the Merger, each issued and outstanding ordinary share of Wize Israel was automatically converted into 4.1445791236989 shares (the "Exchange Ratio") (such number not being converted as per the Reverse Stock Split described in Note 12c) of the Company's common stock, par value $0.001 per share (the "Common Stock"). As a result, an aggregate of 3,915,469 shares, or approximately 90% of the issued and outstanding Common Stock were issued to Wize Israel's shareholders. The pre-Merger stockholders of the Company retained an aggregate of 435,053 shares, or approximately 10% of the issued and outstanding Common Stock.

Significant Accounting Polici_4

Significant Accounting Policies (Details) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies [Abstract]
Currencies	$ 3.748	$ 3.467
Currencies percentage	8.10%	(9.80%)

Significant Accounting Polici_5

Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Cash and cash equivalents	$ 3,183	$ 215	$ 40
Restricted cash		12
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 3,183	$ 227	$ 40

Significant Accounting Polici_6

Significant Accounting Policies (Details 2)	Dec. 31, 2018
Computers and electronic equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	33.00%
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10.00%

Significant Accounting Polici_7

Significant Accounting Policies (Details 3) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Significant Accounting Policies [Abstract]
Balance at December 31, 2016	$ 34
Change in the fair value of derivative liability	246
Reclassification of derivative liability into equity	(280)	[1]
Balance at December 31, 2017
[1]	Upon the December 2017 modification, and in accordance with ASC 815-40 "Derivatives and Hedging, Contracts in Entity's Own Equity", it was determined that the right to future investment is eligible to be considered as indexed to the Company's own stock. Accordingly, the fair value of the Right of Future Investment immediately prior to the Modification Date (December 2017) which amounted to NIS 1,042,000 (approximately $280 according to the exchange rate as of the Modification Date) was reclassified from a derivative liability to additional paid-in capital.

Significant Accounting Polici_8

Significant Accounting Policies (Details 4) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net loss		$ (3,279)	$ (2,966)
Add: Loss attributed to preferred stock	[1]	147
Less: Deemed dividend with respect to right for future investment		292	3
Net loss applicable to stockholders of Common Stock		$ (3,571)	$ (2,969)
Denominator:
Shares of common stock used in computing basic and diluted net loss per share		5,649,262	3,438,842
Net loss per share of Common stock, basic and diluted		$ (0.61)	$ (0.86)
[1]	During the year ended December 31, 2018 the Company issued preferred stock as part of the October 2018 transaction. These preferred shares are participating securities as described in Note 12.j. During the years ended December 31, 2018 and 2017 there were no other potentially dilutive instruments.

Significant Accounting Polici_9

Significant Accounting Policies (Details 5) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Significant Accounting Policies [Abstract]
Balance at January 1, 2017	$ (47)
Cumulative effect adjustment as a result from transition to ASU 2016-01	(26)
Balance at December 31, 2018	$ (73)

Significant Accounting Polic_10

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies (Textual)
Percentage of deposits.	8.33%
Severance expense	$ 10	$ 10
Income tax benefit, description	The tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.
Unrecognized tax
Future investment description	The fair value of the Right of Future Investment immediately prior to the Modification Date (December 2017) was NIS 1,042,000 (approximately $280 according to the exchange rate as of the Modification Date). Such amount was reclassified from a derivative liability to additional paid-in capital.
Derivative liability	$ 0	$ 0

Marketable Equity Securities (D

Marketable Equity Securities (Details)	12 Months Ended
	Dec. 31, 2018shares
Marketable Equity Securities (Textual)
Ordinary shares investment holding	52,249
Percentage of issued and outstanding share	0.12%

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Current Assets [Abstract]
Prepaid expenses	$ 97	$ 3
Receivables from governmental authorities	75	37
Other	8
Other current assets	$ 180	$ 40

License Agreement (Details)

License Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Dec. 31, 2018	May 31, 2015
License Agreement (Textual)
Price per unit			$ 0.60
Percentage of discount rate		21.00%
Fair value of commitment amount		$ 397
Payments for future royalties amounts	$ 185	$ 250

License Purchase Obligation (De

License Purchase Obligation (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Repayment dates:
January 1, 2018		$ 250
January 1, 2019	250
Remaining balance	250	250
Current liability	250	250
Non-current liability
Total	$ 250	$ 250

License Purchase Obligation (_2

License Purchase Obligation (Details Textual) - USD ($) $ in Thousands	1 Months Ended					12 Months Ended
	Feb. 28, 2019	Jan. 21, 2018	Jul. 31, 2017	Jan. 31, 2016	May 31, 2015	Dec. 31, 2018	Sep. 30, 2017
License Purchase Obligation (Textual)
Additional liability minimum commitment							$ 150
Minimum royalty payment obligation, description		Resdevco agreed to postpone the minimum royalty payment obligation amounting to $150 from January 1, 2018 to July 29, 2018.
Subsequent Event [Member]
License Purchase Obligation (Textual)
Reduced annual royalties description	In February 2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through 2021, and then annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt of FDA approval for eye drops utilizing the licensed technology.
License Agreement [Member]
License Purchase Obligation (Textual)
Licensing fees and royalties			$ 150	$ 150	$ 100
Reduced annual royalties description			Wize Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 will be reduced to $150 for 2018 and 2019. If Wize Israel obtains an FDA marketing license during 2019, the Company will be required to pay Resdevco the remainder of the payment of 2019. Consequently, during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the 2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 the Company has recognized an amount of $150 as a liability in respect to the 2019 minimum commitment.
Minimum royalty payment obligation, description						Wize Israel undertook to pay a Minimum Commitment of licensing fees and royalties of no less than $500 in the first three years of the agreement. An amount of $100 was paid in May 2015, upon signing the License Agreement and amounts of $150 and $150 were paid in January 2016 and July 2017, respectively.

Other Accounts Payable (Details

Other Accounts Payable (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Other Accounts Payable [Abstract]
Employees and payroll accruals	[1]	$ 130	$ 101
Accrued expenses		142	95
Total other accounts payable		$ 272	$ 196
[1]	As of December 31, 2018 and 2017, most of the sum refers to a debt to the Company's Chief Executive Officer, with whom the Company had reached an agreement regarding postponing the payment date. The debt is expected to be paid in the foreseeable future.

Convertible Loans (Details)

Convertible Loans (Details) $ / shares in Units, $ in Thousands	Dec. 31, 2018USD ($)$ / shares
Short-term Debt [Line Items]
Aggregate principal amount	$ 1,353
2017 Loan [Member]
Short-term Debt [Line Items]
Aggregate principal amount	$ 822	[1]
Conversion price per Company's share | $ / shares	$ 1.1112
Aggregate maximum of Right to Future Investment	$ 1,233	[2]
Exercise Price of Right to Future Investment | $ / shares	$ 1.332
2016 Loan [Member]
Short-term Debt [Line Items]
Aggregate principal amount	$ 531
Conversion price per Company's share | $ / shares	$ 0.9768
Aggregate maximum of Right to Future Investment	$ 797
Exercise Price of Right to Future Investment | $ / shares	$ 1.308
[1]	Principal loan amount of $274 for each of the three 2017 Lenders.
[2]	Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders.

Convertible Loans (Details 1)

Convertible Loans (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Roll forward of 2017 Loan and 2016 Loan
Opening balance	$ 3,204	$ 289
Proceeds from issuance of 2017 loan, net of issuance cost		811
Recognition of BCF as a discount of 2017 Loan		(811)
Amortization of premium related to convertible loans prior to 2018 modification	(1,458)
Amortization of discounts resulting from BCF and derivative liability and debt issuance costs related to 2017 Loan and 2016 Loan		1,122
Accrued interest on 2017 Loan and 2016 Loan	56	47
Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments	(1,680)	(1,458)
Amount allocated to 2016 and 2017 Loan based on modified terms	3,204	3,204
Amortization of premium related to convertible loans following 2018 modification	(691)
Closing balance	$ 2,635	$ 3,204

Convertible Loans (Details Text

Convertible Loans (Details Textual) ₪ / shares in Units, $ / shares in Units, $ in Thousands	Dec. 21, 2017USD ($)	Jan. 15, 2017USD ($)$ / shares	Jan. 15, 2017ILS (₪)	Mar. 20, 2016USD ($)$ / shares	Mar. 20, 2016ILS (₪)	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2018ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2018ILS (₪)	Jan. 15, 2017ILS (₪)₪ / shares	Mar. 20, 2016ILS (₪)₪ / shares
Convertible Loans (Textual)
Principal amount						$ 2,590		$ 2,544
Average exchange rate						811	₪ 3,000,000
Initial recognition amount | ₪									₪ 0
Deemed dividend	$ 3
Gain on extinguishment of loan						(1,709)		(61)
Additional paid- in capital	$ 1,115					30,272		23,397
Rimon Gold [Member] | Wize Israel [Member]
Convertible Loans (Textual)
Loan amendment, description	The Company entered into an amendment (the "2017 Loan Amendment") to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS.
2017 Lenders [Member]
Convertible Loans (Textual)
Principal amount						274
Right future investment						$ 411
2017 Loan [Member]
Convertible Loans (Textual)
Principal amount								2,985
Conversion price | $ / shares						$ 1.1112
Right future investment						$ 1,336		704
Aggregate amount of loan						3,286
Fair value						1,154		701
Deemed dividend						182
Gain on extinguishment of loan	$ 61					$ 1,709
2017 Loan [Member] | Wize Israel [Member]
Convertible Loans (Textual)
Principal amount		$ 822								₪ 3,000,000
Interest rate		4.00%								4.00%
Maturity date		Dec. 31, 2018	Dec. 31, 2018
2017 Loan [Member] | Rimon Gold [Member]
Convertible Loans (Textual)
Principal amount				$ 531
Conversion price | $ / shares				$ 0.9768
Right future investment				$ 797
Exchange ratio, description				The Exchange Ratio from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment (as defined below), from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events).	The Exchange Ratio from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment (as defined below), from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events).
2017 Loan [Member] | 2017 Lenders [Member]
Convertible Loans (Textual)
Principal amount		$ 822
Interest rate		120.00%								120.00%
Converted instrument, amount		$ 28	₪ 100,000
Conversion price | (per share)		$ 6.72								₪ 24
Right future investment		$ 1,233
Exchange ratio, description		The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15).	The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15).
Converted debt, description		The 2017 Loan Conversion Price was adjusted to $1.1112.	The 2017 Loan Conversion Price was adjusted to $1.1112.
Fixed exercise price | $ / shares		$ 1.332
2017 Loan [Member] | Rimon Gold and Shimshon Fisher [Member]
Convertible Loans (Textual)
Principal amount		$ 274								₪ 1,000,000
2016 Loan [Member]
Convertible Loans (Textual)
Principal amount								$ 2,104
Conversion price | $ / shares						$ 0.9768
Right future investment						$ 874
Aggregate amount of loan						2,314
Fair value						764
Deemed dividend						110
Gain on extinguishment of loan	61					$ 1,709
Additional paid- in capital	$ 61
2016 Loan [Member] | Wize Israel [Member]
Convertible Loans (Textual)
Principal amount				$ 531							₪ 2,000,000
Interest rate				4.00%							4.00%
Maturity date				Dec. 31, 2018	Dec. 31, 2018
2016 Loan [Member] | Rimon Gold [Member]
Convertible Loans (Textual)
Converted instrument, amount				$ 26	₪ 100,000
Conversion price | (per share)				$ 3.84							₪ 15.2592
Exchange ratio, description				As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96).	As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96).

Controlling Shareholder (Detail

Controlling Shareholder (Details) $ in Thousands	Mar. 31, 2017USD ($)	Mar. 31, 2017ILS (₪)	Feb. 19, 2017USD ($)	Feb. 19, 2017ILS (₪)	Dec. 31, 2016USD ($)	Dec. 31, 2016ILS (₪)	Dec. 25, 2016USD ($)	Dec. 25, 2016ILS (₪)	Nov. 15, 2016USD ($)	Nov. 15, 2016ILS (₪)
Controlling Shareholder (Textual)
Short-term bridge loan					$ 27	₪ 100,000
Wize Israel [Member]
Controlling Shareholder (Textual)
Short-term bridge loan			$ 55	₪ 200,000	52	200,000
Total balance amount of the short-term bridge loans					$ 117	₪ 450,000
Wize Israel and Ridge [Member]
Controlling Shareholder (Textual)
Short-term bridge loan	$ 206	₪ 750,000
Shareholder [Member] | Wize Israel [Member]
Controlling Shareholder (Textual)
Short-term bridge loan							$ 78	₪ 300,000	$ 65	₪ 250,000
Interest rate					0.10%	0.10%

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Taxes on Income [Abstract]
Domestic		$ (1,810)	$ (2)
Foreign	[1]	(1,469)	(2,964)
Loss before taxes		$ (3,279)	$ (2,966)
[1]	Relates to Wize Israel.

Taxes on Income (Details 1)

Taxes on Income (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Operating loss carry forward	$ 2,097	$ 1,688
Reserves and allowances	6	8
Research and development	136	89
Net deferred tax asset before valuation allowance	2,239	1,785
Valuation allowance	(2,239)	(1,785)
Net deferred tax asset

Taxes on Income (Details 2)

Taxes on Income (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Taxes on Income [Abstract]
Loss before taxes on income, as reported in the statements of comprehensive loss	$ (3,279)	$ (2,966)
Theoretical tax benefit on this loss	689	716
Expenses not deductible for tax purposes	(72)	(51)
Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized	(617)	(665)
Tax benefit

Taxes on Income (Details Textua

Taxes on Income (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017
Taxes on Income (Textual)
Percentage of income tax, description	(i) establish a flat corporate income tax rate of 21% to replace current rates that range from 15% to 35% and eliminates the corporate alternative minimum tax; (ii) create a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time transition tax; (iv) create a "minimum tax" on certain foreign earnings and a new base erosion anti-abuse tax (BEAT) that subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum deduction for Net Operating Loss (NOL) carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer's taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried forward indefinitely and generally repeals carrybacks; (vii) elimination of foreign tax credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi) repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions and credits, and adds other provisions that broaden the tax base.
Corporate and deferred tax, description		The provisional amount related to the re-measurement of our net U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but which was fully and equally offset by a corresponding reduction in the Company's valuation allowance. The effect of the change in federal corporate tax rate from 34% to 21% is subject to change based on resolution of estimates used in determining the amounts of deferred tax assets and liabilities that were re-measured.
Net operating loss carryforwards for federal income tax		$ 3,811
Tax credit carryforward, description		The annual net operating loss carry forward (pre merger, approximately $2,734) is limited to $10.965 per year.
Net operating loss carry forwards		$ 1,120
Accumulated losses for tax		(73)	$ (47)
Wize Israel [Member]
Taxes on Income (Textual)
Accumulated losses for tax		7,980
Ocuwize [Member]
Taxes on Income (Textual)
Accumulated losses for tax		$ 1,050
Israel [Member]
Taxes on Income (Textual)
Corporate tax rate		23.00%	24.00%
Israel [Member] | Minimum [Member]
Taxes on Income (Textual)
Corporate tax rate		23.00%	24.00%
Israel [Member] | Maximum [Member]
Taxes on Income (Textual)
Corporate tax rate		24.00%	25.00%

Commitments and Contingencies (

Commitments and Contingencies (Details)	Nov. 22, 2018	Jun. 19, 2017
Commitments and Contingencies (Textual)
Rent agreement, description	The Company rents its offices from a third party for a rental monthly fee of $ 2. The rent period is for a period of 12 months with an option to extend the lease period for additional 12 months.
Vendor [Member]
Commitments and Contingencies (Textual)
Percentage of royalty rate		5.00%
Finder’s fee agreement, description		The service provider will be entitled to the finder fee of 5% even if the agreement will be terminated.

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details) - 2012 Plan [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of options
Options outstanding at beginning of year | shares	4,896
Granted | shares
Options outstanding and exercisable as of December 31, 2018 | shares	4,896
Weighted average exercise price
Options outstanding at beginning of year | $ / shares	$ 190.8
Granted | $ / shares
Options outstanding and exercisable as of December 31, 2018 | $ / shares	$ 190.8
Weighted average remaining contractual life
Options outstanding at beginning of year	4 years 10 months 10 days
Options outstanding and exercisable as of December 31, 2018	4 years 1 month 9 days

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 1) - 2018 Plan [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of options
Beginning balance | shares
Granted | shares	255,000
Ending balance | shares	255,000
Options exercisable as of December 31, 2018 | shares	38,246
Weighted average exercise price
Beginning balance | $ / shares
Granted | $ / shares	3.68
Ending balance | $ / shares	3.68
Options exercisable as of December 31, 2018 | $ / shares	$ 3.59
Weighted average remaining contractual life
Granted	6 years 6 months 18 days
Options outstanding as of December 31, 2018	6 years 6 months 18 days
Options exercisable as of December 31, 2018	6 years 2 months 30 days

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details Textual) $ / shares in Units, $ in Thousands

Aug. 15, 2018$ / sharesshares

Apr. 04, 2018$ / sharesshares

Dec. 11, 2017

Oct. 22, 2018USD ($)$ / sharesshares

Oct. 19, 2018

Jul. 31, 2018shares

Jun. 30, 2018shares

Apr. 30, 2018shares

Feb. 22, 2018shares

Feb. 19, 2018

Jun. 23, 2017

Jun. 22, 2017

May 10, 2018

Jun. 30, 2018USD ($)

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Feb. 28, 2018shares

Dec. 31, 2017ILS (₪)shares

Stockholders' Deficit (Textual)

Future investment exercised | $

$ 1,176

Future investment exercised, shares

267,000

Company received amount of common stock | $

$ 16

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Exercise of options into common stock | $

$ 21

Warrants remain outstanding

788,658

788,658

Aggregate exercise price of warrants | $

$ 1,145

Common stock shares issued

8,957,550

4,350,608

4,350,608

Registration statement, description

The Company filed an amendment to the S-1 Registration Statement, for the purpose of registering (i) 922,330 shares of Common Stock that were outstanding as of that date; and (ii) 338,945 shares of Common Stock which are issuable upon conversion of the 2016 Loan and/or the 2017 Loan. On July 12, 2018, the S-1 Registration Statement has been declared effective by the SEC.

Common stock value issued for services | $

$ 54

Common stock shares issued for services

55,000

Restricted stock units, value | $

$ 471

Vest options exercisable, term

2 years 6 months

Unrecognized compensation cost | $

$ 295

Contractual term of stock-based grants, description

The Company and five representative companies and expected term of stock-based grants of 7 years.

Purchase agreement, description

The Company granted to the investors thereunder, for a period of three years from the closing date of the Purchase Agreement, a right of participation of up to an aggregate of 35% in any subsequent offering of the Company, subject to certain exceptions.

Warrant term, description

The Series A Warrants have a term of 5 years from issuance, and the Series B Warrants will have a term that expires 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) has occurred, the expiration date of the Series B Warrants will be extended by one day.

Trading activities, description

During the period commencing upon execution of the Purchase Agreement, and expiring on the trading day immediately following the date that the Company has raised, beginning after the issuance date of the Warrants, at least $10 million in gross proceeds from the issuance of the Company's securities, the Company issues or sells common stock (or securities convertible into or exercisable into common stock) at a purchase price (or conversion or exercise price, as applicable) lower than the exercise price of the Warrants, than the exercise price of the Warrants will be reduced to such lower price, subject to certain exceptions.

Exercise price of warrants | $ / shares

$ 1

Legal expenses | $

$ 50

Non-accountable expense allowance | $

$ 30

Maturity date, description

(i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date.

Investor [Member]

Stockholders' Deficit (Textual)

Ownership, percentage

9.99%

Liquidated damages to investors, description

The Company shall pay to each investor cash equal to 2% of such investor's total purchase price on the dates of each deficiency and on the 30th day after such deficiencies until such deficiencies are cured, up to a maximum of 10% of the purchase price.

Beneficial Owner [Member]

Stockholders' Deficit (Textual)

Ownership, percentage

4.99%

Mesodi [Member]

Stockholders' Deficit (Textual)

Future investment exercised, shares

89

Fee amount | $

$ 89

Series A Preferred Stock [Member]

Stockholders' Deficit (Textual)

Common stock value issued for services | $

$ 440

Common stock shares issued for services

440,000

Purchase agreement, description

(i) 150 days following the date that all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, (ii) six months after the date that a non-affiliate investor under the Purchase Agreement may first sell securities purchased thereunder under Rule 144, (iii) 120 days following the listing of the common stock on a Qualified Market (as defined below) and (iv) the first trading day that the weighted average price of the common stock exceeds $5.00 per share for 10 consecutive trading days.

Series A Certificate of Designations [Member]

Stockholders' Deficit (Textual)

Preferred stock, designated

1,350

Preferred stock stated value | $

$ 1,000

Shares of common stock, dividing | $

$ 1,000

Conversion price | $ / shares

$ 1

Converted instrument, shares

1,000

Series A Certificate of Designations [Member] | Investor [Member]

Stockholders' Deficit (Textual)

Ownership, percentage

9.99%

Series A Certificate of Designations [Member] | Beneficial Owner [Member]

Stockholders' Deficit (Textual)

Ownership, percentage

4.99%

Service Providers [Member]

Stockholders' Deficit (Textual)

Common stock value issued for services | $

$ 381

Common stock shares issued for services

67,778

Two Service Providers [Member]

Stockholders' Deficit (Textual)

Common stock value issued for services | $

$ 126

Common stock shares issued for services

24,306

24,306

2012 Plan [Member]

Stockholders' Deficit (Textual)

Granted term in excess

10 years

Reserved for issuance, common stock

45,370

Common stock, par value | $ / shares

$ 0.001

Common stock available for future grant

40,474

Common stock outstanding and exercisable

4,896

Restricted Stock Units (RSUs)

Stockholders' Deficit (Textual)

Number of options, granted

131,200

Officer [Member]

Stockholders' Deficit (Textual)

Common stock outstanding and exercisable

229,500

Registration statement, description

295

Common stock shares issued for services

131,200

Options outstanding and exercisable | $ / shares

$ 3.59

Vest options exercisable, term

36 months

Board of Directors [Member]

Stockholders' Deficit (Textual)

Reverse stock split, description

The Company announced a notice of special meeting of stockholders, according to which, a special meeting of the stockholders was held on February 19, 2018, for the purpose of considering to grant the Company's Board of Directors the authority, in its sole direction, to approve an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200.

The Company's Board of Directors approved a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of 1-for-24 ("Reverse Stock Split").

The stockholders of the Company approved a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200 at any time prior to February 19, 2019, with such ratio to be determined by the Company's Board of Directors, in its sole discretion.

Common stock outstanding and exercisable

229,500

Registration statement, description

295

Common stock shares issued for services

131,200

Options outstanding and exercisable | $ / shares

$ 3.59

Vest options exercisable, term

36 months

Consultant [Member]

Stockholders' Deficit (Textual)

Common stock outstanding and exercisable

25,500

229,500

Registration statement, description

295

Common stock shares issued for services

131,200

Options outstanding and exercisable | $ / shares

$ 4.50

$ 3.59

Vest options exercisable, term

36 months

36 months

2018 Plan [Member] | Board of Directors [Member]

Stockholders' Deficit (Textual)

Description of investments

(i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.

Common stock shares issued

2,500,000

2018 Plan [Member] | Directors, Officers and Consultant [Member]

Stockholders' Deficit (Textual)

Number of options, granted

255,000

2016 Investment Right [Member]

Stockholders' Deficit (Textual)

Future investment exercised | $

$ 853

Future investment exercised, shares

217,442

Shares of common stock, per share | $ / shares

$ 1.308

2017 Investment Right [Member]

Stockholders' Deficit (Textual)

Future investment exercised | $

$ 853

Future investment exercised, shares

427,048

Shares of common stock, per share | $ / shares

$ 1.332

Private Placement Agreement [Member]

Stockholders' Deficit (Textual)

Description of investments

Pursuant to the 2017 PIPE Agreements, the 2017 PIPE Investors agreed to invest a total of NIS 3,490,000 (approximately $966) in exchange for a total of 860,987 ordinary shares of Wize Israel (the "2017 PIPE"), at a price per share of NIS 4.05 (approximately $1.15), with Peretz undertaking to invest NIS 490,000 (approximately $139 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 120,884 ordinary shares of Wize Israel (the "Peretz Investment") and each of Zrachia, Sadan and Rubini (the "Other Investors") undertaking to invest NIS 1,000,000 (approximately $282 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 246,701 ordinary shares of Wize Israel each (together, the "Other Investments"). Subject to the Closing Date of the Merger, Wize Israel also undertook to cause the Company to grant warrants to each of the 2017 PIPE Investors Warrants, with each Warrant being exercisable into one share of the Company's common stock, par value $0.001 per share (the "Common Stock"), with a term of three years from the date of grant.

Private Placement Agreement [Member] | Series A Preferred Stock [Member]

Stockholders' Deficit (Textual)

Purchase agreement, description

(i) 3,100,000 shares of common stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of common stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also issued to the investors Series A warrants (the "Series A Warrants") to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)), and Series B warrants (the "Series B Warrants, and together with the Series A Warrants, the "Warrants"), to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants have an exercise price of $1.10 per share, and the Series B Warrants have an exercise price of $1.00 per share.

Warrants [Member]

Stockholders' Deficit (Textual)

Description of investments

(i) 30,625 warrants to Peretz and (ii) 62,500 warrants to each of the Other Investors, each warrant exercisable into one ordinary share of Wize Israel, at an exercise price of NIS 28.8 per share (approximately $8.4 according to the exchange rate as of December 31, 2017). According to the Exchange Ratio, Peretz was granted 126,928 Warrants exercisable into Common Stock and each of the Other Investors was granted 259,036 Warrants exercisable into Common Stock. Sadan's commitment to provide his portion of the Other Financing was conditioned upon Wize Israel not raising more than NIS 3,500,000 (approximately $988 according to the exchange rate as of June 23, 2017) and not less than NIS 2,000,000 (approximately $565 according to the exchange rate as of June 23, 2017) in the 2017 PIPE, including the amount to be invested by Sadan.

Issued shares of common stock

144,168

Warrants exercised shares of common stock

144,168

Warrants remain outstanding

759,871

Aggregate exercise price of warrants | $

$ 292

Peretz Investment and Other Investments [Member]

Stockholders' Deficit (Textual)

Future investment exercised

$ 1,000

₪ 3,490,000

Future investment exercised, shares

860,987

860,987

Exchange rate, description

The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted from NIS 24.00 (approximately $6.72 according to the exchange rate as of June 23, 2017) to NIS 16.8 (approximately $4.8 according to the exchange rate as of June 23, 2017) and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment (see note 8 above), the aggregate principal amount of the 2017 Loan is $822,144 and the 2017 Loan Conversion Price was adjusted to $1.1112.

Selected Statements Of Operat_3

Selected Statements Of Operations Data (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	$ (2,936)	$ (1,031)
Overseas travel [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	118	72
Share-based payment [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	783
Rent and office maintenance [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	46	53
Payroll and benefits [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	518	300
Professional services and consultation [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	1,051	472
Taxes and tolls [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	16	46
Director salary and insurance [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	191	63
Others [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
General and administrative expenses	$ 213	$ 25

Selected Statements Of Operat_4

Selected Statements Of Operations Data (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Financial income:
Amortization of premium related to convertible loans	$ (2,149)
Total finance income	(2,149)
Financial expenses:
Accrued interest on convertible loans	56	47
Change in fair value of marketable equity securities	33
Amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for 2016 Loan		1,122
Amortization of discount and exchange rate differences on license purchase obligation		3
Bank commissions and exchange rates		6
Change in the fair value of derivative liability for right to future investment		246
Loss from extinguishment of convertible loans (Note 8)	1,709	61
Total financial expenses	1,798	1,485
Total financial expenses (income), net	$ 351	$ (1,485)

Related Parties Balances and _3

Related Parties Balances and Transactions (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Balances with interested and related parties:
Other accounts payable	$ 97	$ 54
Convertible Loans	$ 2,590	$ 2,544

Related Parties Balances and _4

Related Parties Balances and Transactions (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Amounts charged to:
General and administrative expenses	$ 1,209	$ 263
Finance expenses, net (income)	$ (306)	$ 1,181

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - shares	Mar. 04, 2019	Mar. 01, 2019	Feb. 07, 2019	Mar. 31, 2019
Subsequent Events (Textual)
Convertible loan agreement, description	Pursuant to the Amendment, the maturity date under the (i) convertible loan agreement between Wize Israel and Rimon Gold, dated March 20, 2016 (as amended, the "2016 Loan Agreement"), and (ii) convertible loan agreement, dated January 12, 2017 (as amended, the "2017 Loan Agreement"), among Wize Israel, Rimon Gold, and Ridge Valley, was extended to May 31, 2019 (as previously described under the 2018 Loan Modification) from March 4, 2019. The parties also agreed that the Lenders' investment rights under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and the Lender's investment rights under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from June 30, 2019 to November 30, 2019.
Common stock shares issued		900,000	900,000
Officers [Member]
Subsequent Events (Textual)
Restricted stock units grant shares				140,000
Restricted stock units vest term				24 months
Directors [Member]
Subsequent Events (Textual)
Restricted stock units grant shares				100,000
Restricted stock units vest term				24 months
Cannabics Pharmaceuticals [Member]
Subsequent Events (Textual)
Common stock shares issued		2,263,944	2,263,944
Ownership, percentage			50.00%